[LOCATION_011] Scientific 
ClinicalTrials. gov NC T #: [STUDY_ID_REMOVED] 
Study Title: Efficacy Evaluation of TheraSphere in Patients 
With Inoperable Liver Cancer (STOP-HCC)
Approved Document Date: 22 July 2019 
Redacted Document D ate: 28 April 2023  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 1 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  Protocol Number:  TS-103 
Protocol Short Title:  STOP-HCC 
Protocol Name:  A Phase III Clinical Trial of Intra -arterial Thera Sphere® in the 
Treatment of Patients with Unresectable Hepatocellular 
Carcinoma ( HCC)  
US Sponsor :  
BTG International  Inc. 
 
 
                                                                                      
  
Global Sponsor:  Biocompatibles [LOCATION_006]  Ltd 
 
 
 
 
Global Principal 
Investigator   
  
 
 
 
 
  
[INVESTIGATOR_605607]:   TheraSphere ®, Yttrium -90 Glass Microspheres  
FDA File #: IDE 100322  
CE Mark for EU sites only  CE 0123  
Protocol Activat ion Date :  2011/03/09  (YYYY/MM/DD)   
                                                                 
TheraSphere® is a trademark of Theragenics Corporation used under license by [CONTACT_605630]. BTG and the BTG 
roundel logo are trademarks of BTG International Ltd, and are registered  trademarks in the US, EU and certain other territories. All 
rights  reserved.  
This document is the confidential property of the Sponsor. No part of it may be transmitted, reproduced, published, or used b y other 
persons without prior written authorization.  
 

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 2 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019   
Amendments:  Version 2.0 2012/01/ 24 (YYYY/MM/DD)  
Version 3.0 2013/09/ 06 (YYYY/MM/DD)  
Version 4.0 2014/03/04  (YYYY/MM/DD)  
Version 4.1 2014/05/2 0 (YYYY/MM/DD)  
Version 5.0 2015/01 /08  (YYYY/MM/DD)  
Version 6.0 2016/0 8/24  (YYYY/MM/DD ) 
Version 6.1 2016/11/ 29  (YYYY/MM/DD ) 
Version 7.0 2019/ 07/22 (YYYY/MM/DD)  
   
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 5 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019   
 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 6 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019   
INVESTIGATOR’S PROTOCOL REVIEW STATEMENT  
 
By [CONTACT_27616], I confirm that my staff and I have carefully read and understand the protocol, A 
Phase III Clinical Trial of Intra -arterial Th eraSphere in the Treatment of Patients with Unresectable 
Hepatocellular Carcinoma (HCC) , and agree to conduct the trial in accordance with the protocol, the 
appropriate regulations specified in the protocol, and the stipulations of the clinical study agree ment  
 
 
__________________________________________   ________________  
Investigator        Date  
__________________________________________   ________________  
Investigator  Printed Name  
 
 
   [CONTACT_605669]-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802023] OF ABBREVIATION S ................................ ................................ ................................ .............  24 
5.0 BACKGROUND AND RATIO NALE  ................................ ................................ ................................ . 26 
5.1 GENERAL DEVICE DESCRIPTION  ................................ ................................ ................................ .............  26 
5.2 GLOBAL REGULATORY STATUS OF THERA SPHERE  ................................ ................................ ......................  26 
5.3 RATIONAL E FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA  ................................ ............................  26 
5.4   ................................ ................................ .................  29 
6.0 STUDY OBJECTIVE  ................................ ................................ ................................ .......................  29 
7.0 STUDY DESIGN  ................................ ................................ ................................ ............................  30 
8.0 STUDY POPULATION AND  ELIGIBILITY CRITERI A ................................ ................................ .........  30 
8.1 ELIGIBILITY CRITERIA  ................................ ................................ ................................ ...........................  30 
9.0 STUDY VISITS, EVALUA TIONS AND PROCEDURES  ................................ ................................ ........  32 
9.1 STUDY VISITS ................................ ................................ ................................ ................................ ..... 32 
9.1.1  Screening/Randomization (Days -14 to Day 0)  ................................ ................................ ...... [ADDRESS_802024]  ................................ ................................ ................................ ......................  37 
9.2.11 Review Eligibility Criteria  ................................ ................................ ................................ .......  37 
9.2.12  HCC Tumor Biomarker  ................................ ................................ ................................ ...........  37 
9.2.13  Quality of Life  ................................ ................................ ................................ ........................  37 
9.2.14  Randomization (Study Day 0)  ................................ ................................ ................................  37 
9.2.15  Study Treatments  ................................ ................................ ................................ ..................  38 
9.2.16  Efficacy Imaging – CT/MRI  ................................ ................................ ................................ .... [ADDRESS_802025]  ................................ ................................ .....................  46 

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802026]  ................................ ................................ ..............................  46 
9.2.20  Study completion  ................................ ................................ ................................ ...................  46 
10.0  STATISTICS  ................................ ................................ ................................ ................................ .. 47 
10.1  SAMPLE SIZE ESTIMATE  ................................ ................................ ................................ .......................  47 
10.2  STATISTICAL ANALYSIS PLAN ................................ ................................ ................................ .................  48 
10.2.1  Populations and Sub -Groups  ................................ ................................ ................................ . 48 
10.2.2  Trial Endpoints  ................................ ................................ ................................ .......................  48 
10.2.3  Efficacy Analysis ................................ ................................ ................................ .....................  50 
10.2.4  Safety Analys es ................................ ................................ ................................ ......................  52 
10.2.5  Poolability and Other Analyses  ................................ ................................ ..............................  53 
10.2.6  Independent Data Monitoring Committee  ................................ ................................ ............  54 
10.2.7   ................................ ................................ ............................  54 
11.0  DATA COLLECTION AND MANAGEMENT  ................................ ................................ .....................  54 
11.1  ELECTRONIC DATA COLLEC TION (EDC)  ................................ ................................ ................................ ... 54 
11.2  DATA MANAGEMENT  ................................ ................................ ................................ ..........................  55 
12.0  ADVERSE EVENTS  ................................ ................................ ................................ ........................  55 
12.1  ADVERSE EVENT DEFINITIONS  ................................ ................................ ................................ ...............  55 
12.1.1  Definitions of AE/SAE for Drugs  ................................ ................................ .............................  55 
12.1.2  Definitions of ADE/SADE/UADE for devices  ................................ ................................ ...........  56 
12.2  RECORDING ADVERSE EVENTS  ................................ ................................ ................................ ...............  56 
12.2.1  Causality (Relationship to Medical Device) Assessment  ................................ ........................  [ADDRESS_802027] OF RESEARCH  ................................ ................................ ................................ .... 62 
13.7  INFORMED CONSENT  ................................ ................................ ................................ ...........................  63 
13.8  PATIENT MEDICAL RECORDS  ................................ ................................ ................................ .................  63 
13.9  PATIENT PRIVACY AND CONFIDENTIALITY ................................ ................................ ................................ . 63 
13.10  ADDITIONAL INVESTIGATOR RESPONSIBILITIES  ................................ ................................ ......................  64 
14.0  PROTOCOL DEVIATIONS  ................................ ................................ ................................ ..............  64 
15.0  MAJOR AND MINOR P ROTOCOL DEVIATIONS  ................................ ................................ .............  64 
16.0  STUDY MONITORING  ................................ ................................ ................................ ..................  65 
17.0  STUDY TERMINATION  ................................ ................................ ................................ .................  65 

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 9 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  APPENDICES  ................................ ................................ ................................ ................................ ...........  66 
REFERENCES  ................................ ................................ ................................ ................................ ...........  67 
 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 10 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  1.0 PROTOCOL SYNOPSIS  
Protocol Number  TS-103 
Protocol Short Title  STOP -HCC  
Protocol Title  A Phase III Clinical Trial of Intra -arteri al TheraSphere in the Treatment of Patients 
with U nresectable Hepatocell ular Carcinoma (HCC)  
 
Device  TheraSphere, Yttrium -[ADDRESS_802028] appropriately positioned arterial catheters.  
TheraSphere is currently approved for commercial distribution  in the [LOCATION_002] 
under a Humanitarian Device Exemption (HDE) for use in radiation treatment or as a 
neoadjuvant to surgery or transplantation in patients with unresectable 
hepatocellular carcinoma (HCC) who can have placement of appropriately positioned 
hepatic arterial catheters.  The device is also indicated for H CC patients with partial 
or branch portal vein thrombosis/occlusion, when clinical evaluation warrants the 
treatment.  
Standard -of-care 
Systemic therapy  Sorafenib  
Type of Protocol  Phase III  
Protocol Design  This is an open -label, prospective, multi -cente r, randomized  clinical trial.  
Study  Objective  To evaluate TheraSphere in the treatment of patients  with  unresectable 
hepatocellular carcinoma  in who m treatment with  standard -of-care sorafenib 
therapy  is planned . 
Primary Endpoint  
 Overall Survival (OS)  from time of randomization  
Secondary Endpoints   Time to progression (TTP) from time of randomization based on investigator 
assessment according  RECIST criteria v 1.1  
 Time to untreatable progression (TTUP)  from the time of randomization 
based one or more of  the following: investigator assessment according to 
RECIST criteria v 1.1, contraindication to protocol treatments based on 
package insert or patient performance status.   
 Time to symptomatic progression (TTSP)  from the time of randomization  to 
ECOG perf ormance status > [ADDRESS_802029] criteria v 1.1 . Deterioration in 
performance status is to be confirmed at two subsequent evaluation s at 8 
week  intervals.    
 Tumor response  according to RECIST v 1.[ADDRESS_802030] criteria20 and 
based on a blinded centralized independent imaging assessment, will be an 
exploratory endpoint.  
 Quality of life Assessments  (including the Functional Assessment of Cancer 
Therapy – Hepatobiliary Questionnaire – FACT -Hep)  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 11 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019   Adverse events  (NCI-CTAE v 4.0) 
 
 
 
  
     
 
   
   
  
   
   
  
  
 
   
   
  
   
   
  
 
Trial Population  Patients diagnosed with unresectable HCC  who are not eligible for any curative 
procedures  and for whom standard -of-care therapy with sorafenib is planned . 
Number of patients  The randomization of a pproximately 520 patients  is planned, with up to a maximum 
of 700 patients being randomized based on a sample size re -estimation  after the 
second int erim analysis .  
Number of sites  Up to  105 sites in North America , Europe  and Asia  
Treatment Groups   The Control  group  will receive  planned  standard -of-care therapy sorafenib  in 
accordance with the approved product labeling.  
 The Treatment  group  will recei ve TheraSphere  prior to the initiation of 
standard -of-care  sorafenib  treatment .   All liver tumors observed at baseline 
that are amenable to treatment with TheraSphere should be treated with 
TheraSphere prior to the initiation of treatment  with sorafenib .    
Study Duration  Approximately 60 months of accrual and 18 months  additional follow -up is planned ; 
with approximately  66 months of accrual if required following  sample size re-
estimation.    
 

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802031] or MRI (according to RECIST  1.1) 
5. Must have a Child Pugh score < [ADDRESS_802032] an ECOG Performance Status score of ≤ [ADDRESS_802033] a Platelet count > 50 x 109/L or > 50% prothrombin activity  
10. Must have a Hemoglobin ≥ 8 .5 g/dL 
11. Must have Bilirubin ≤  2 .5 mg/dL  
12. ALT and AST  must be  < 5X upper limit of normal  
13. Amylase or lipase  must be ≤ 2X upper limit of normal  
14. Serum creatinine  must be ≤ 1.5X upper limit of normal  
15. INR must be  < 2.[ADDRESS_802034] m ain portal vein thrombosis ( PVT) (branch porta l vein 
thrombosis is permissible).  
17. Must not be eligible for curative treatment ( e.g ablation or transplantation)  
18. Must not have history of p revious or concurrent cancer other than HCC 
unless treated curatively [ADDRESS_802035] c onfirmed presence of extra -hepatic disease except  lung 
nodules and mesenteric or portal lymph nodes ≤ 2.[ADDRESS_802036]  tumor replacement >70% of total liver volume based on 
visual estimation by [CONTACT_605631] t umor replacement 
>50% of total liver volume in the prese nce of albumin <3 g/dL  
22. Must not have any history of severe allergy or intolerance to contrast 
agents, narcotics sedatives or atropi[INVESTIGATOR_605608]  
23. Must not have any c ontraindications to angiography and selective visceral 
catheterization  
24. Must not have history of organ allograft  
25. Must not have a ny known contraindications to sorafenib  including allergic 
reaction, pi[INVESTIGATOR_4382] -swallowing difficulty,  evidence of severe or  uncontrolled  systemic 
diseases,   uncontrolled  severe  hypertension or cardiac  arrhythmias , congestive 
heart  failure >[LOCATION_001] Heart Association  (NYHA)  class 2, myocardial infarct 
within 6 months, prolonged QT/QTc >450ms,  evidence of torsades de pointe,   
or laboratory finding that in the view of the investigator makes it undesirable 
for the patient to participate in the trial  , significant GI bleed within 30 days, 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802037] not be taking any of the following:   Rifampi[INVESTIGATOR_2513], St. John’s Wort, 
phenytoin, ca rbamazepi[INVESTIGATOR_050], phenobarbital, an d dexamethasone  
27. Must not be taking a ny other systemic anticancer agent ( e.g. docetaxel, 
doxorubicin, irinotecan  etc. ) 
28. Must not be taking any s ubstrate agents for CYP2B6 (buproprion, 
cyclophosphamide, efavirenz, ifosfamide, methadone, pacilitaxel, 
amodiaqu ine, repaglinide)  
29. Must not be taking any UGT 1A1 and UGT 1A9 substrates (e.g., irinotecan)  
30. Must not be taking P-Gp substrates (e.g., Digoxin)  
31.  Any prior liver resection must have taken place > 2 months prior to 
randomization  
32. Treatment with other locoregio nal therapi[INVESTIGATOR_014] (other than study treatment) 
has not been planned for the duration of the clinical study period  
33. Has not received any p rior external beam radiation treatment to the  chest,  
liver or abdomen  
34. Has not received any p rior yttrium -90 microsphere trea tment to the liver  
35. Prior treatment with transarterial chemoembolization (TACE) or bland 
embolization  must have occurred  > [ADDRESS_802038] been applied to a treatment field and/or lobe that is not to be treated 
under this proto col. For patients with tumor progression in the treatment field 
and/or lobe previously treated with TA(C)E, vessels feeding the tumor(s) must 
be assessed for adequate blood flow using angiography (cone beam 
computerized tomography (CBCT) strongly recommend ed), and the TACE or 
bland embolization must have been applied >[ADDRESS_802039]  due to prior therapy that is unresolved at 
randomization  
38. Has not received any p rior systemic therapy for the treatment of HCC, 
including sorafenib  given for more than 4 weeks during the 2 previous months 
prior to randomi zation; no prior sorafen ib related toxicity  
39. No evidence of pulmonary insufficiency or  inadequately treated moderate 
grade or severe/very severe grade chronic obstructive pulmonary disease .    
40. Must not have undergone a ny intervention for, or compromise of, the 
Ampulla of Vater  
41. Must not hav e any c linically evident ascites (trace ascites on imaging is 
acceptable)  
42. Must not be p regnant or breast -feeding  
43. Women of childbearing potential must have a  negative serum pregnancy 
test within [ADDRESS_802040] any disease or condition that would preclude the safe use of 
TheraSphere, including concurrent dialysis treatment, or unresolved serious 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802041] not be participating in concurrent clinical trials evaluating treatment 
intervention(s).  
 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 15 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  Imaging Requirements   Triple Phase CT – To determine liver volume measurement, identify hepatic 
vascular anatomy to determine TheraSphere dosimetry  
 Spi[INVESTIGATOR_281375]/pelvis –performed with cuts of [ADDRESS_802042] criteria v1.1.  
 Spi[INVESTIGATOR_281376]  –performed with cuts of [ADDRESS_802043] criteria v 1.1   
 MRI can replace CT scans; however, the same imaging modality should be used  
for all images in an individual patient throughout the study   
 Imag es for efficacy assessments will require a duplicate set of images in DICOM 
format  
Hepatic a ngiography and 99mTc-MAA – selective celiac and superior mesenteric 
arteriograms are needed to evaluate the hepatic arterial anatomy for the whole 
liver, as wel l as evaluation of potential sources of extra -hepatic blood supply to 
tumors. Repeat 99mTc-MAA  may be needed to estimate cumulative lung shunt or 
re-asses GI flow.  
Statistical Plan and 
Sample Size Calculation  This study is an adaptive trial using a group sequential design  with  overall  survival  
(OS)  as the primary efficacy endpoint . 
A modified Intention To Treat (mITT) Population will be used to analyze all efficacy 
endpoints.  This population is defined as randomized patients who met the study 
eligibility  criteria  at randomization . 
The s tudy is designed to detect a 3.5 month increase in median OS time, from 10.7  
months in the sorafenib arm to 14.2 months in the TheraSphere arm (ie, hazard 
ratio = 0.7 54), using a log rank test.   Due to uncertainty in the ex pected treatment 
effect, a sample size re -estimation is planned, which would allow the sample size to 
increase in order to detect a 3. 0 month increase in median OS time, from 10.7  
months in the sorafenib arm to 13.7 months in the TheraSphere arm (ie, hazar d 
ratio = 0.7 81). 
A maximum of 417 deaths will yield 80% power to detect the target difference in 
median OS (ie, hazard ratio = 0.7 54) with a two-sided alpha of 0.05 using a group 
sequential design with 2 interim analyses.  It is  estimated that a maximum o f 520 
patients will need to be recruited over 60 months, with an 18 month  additional 
follow -up period.  This includes an adjustment to take account of an assumed 5% of 
patients who will be lost to follow -up and for whom a date of death is not recorded , 
and an assumed additional 5% of patients who will be  erroneously randomized 
because they did not meet the eligibility criteria at randomization .   
 
 
  
Analysis of primary endpoint  
OS will be compared between treatment arms using a log -rank test.  The hazard 
ratio and corresponding two -sided 95% confidence interval (CI) for the treatment 
effect will be computed.  Kaplan -Meier curves will also be produced.  
Interim analyses of primary endpoint : The first interim analysis is planned at 
approximately, but no less than, 188 deaths, with a two-sided p -value ≤ 0.0151 

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 16 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  allowing the study to be stopped earl y for efficacy.  A second interim analysis is 
planned at approximately, but no less than, 250 deaths, with a two-sided p -value 
≤0.01 51 allowing the study to be stopped early for efficacy.  
A conditional power of less than  or equal to  15% at each of the int erim analyses will 
result in the study stoppi[INVESTIGATOR_605609].  
Sample size modification will be considered at the second interim analysis following 
the approach described in Mehta & Pocock (2011)[ADDRESS_802044] statistic at the fi nal analysis as recommended by [CONTACT_605632] & Sonneson (2006)17. 
Final Analysis of primary endpoint :  The final analysis, without a sample size 
modification, will be performed when approximately, but no less than,  [ADDRESS_802045] occurred .  A two-sided p -value  ≤0.[ADDRESS_802046] occurred , 
which will result in 80% power to detect an improvement in median OS from 10.[ADDRESS_802047] with a final two-sided alpha of 0.0 363. 
Analysis of secondary efficacy endpoints  
Comparison between treatment groups for all secondary endpoints will be 
conducted at the final analysis with a two -sided alpha of 0.05.  
Time to event endpoints (ie, TTP, TTUP, TTSP) will be compared between treatment 
arms using a log -rank test .  Tumor response rates will be compared between 
treatment arms using the continuity adjusted Newcombe -Wilson  test.  The FACT -
Hep score will be compared between treatment arms using a mixed l inear model 
with baseline score and  the relative time from baseline as covariates.  
Safety Anal ysis: All patients who received study treat ments at least once  will 
be inclu ded in the safety analysis. All Adverse events (AE s) will be reported 
accor ding to the National Cancer Institute Common Terminology Criteria for 
Adverse Events v 4.0 (CTCAE) grades and coded using the Me dical Dictionary for 
Regulatory Activities (MedDRA). The incidence of treatment emergent adverse 
events (events which were not present at baseline or worsened in severity 
following the start of treatment) will be summarized according to MedDRA primary 
system-organ class (SOC) and preferred term (PT).   Laboratory  values will be 
summarized  by [CONTACT_605633]. 
A feasibility safety assessment will be conducted after the first [ADDRESS_802048] received both TS and sor afenib therapy.  
Poolability and Other Analysis : Multivariate Cox regression analysis  of time -to-event  
efficacy endpoints  will be conducted on stratification criteria and other factors such 
as age, gender, duration of disease prior to randomization.  
As a s ensitivity analysis, to address the poolability of data across regions, study sites 
and gender, a Cox regression analysis of the primary efficacy endpoint, OS, will be 
conducted with factors of region, study site and gender, and to determine the 
impact of these factors on OS.  Note: region and study site will not be included 
simultaneously in the model due to collinearity.  
Should the impact of region, site or gender on OS be statistically and clinically 
relevant, the reasons for the observed differential tr eatment effect, such as patient 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802049] question as a result of this sensitivity analysis, 
the primary endpoint (OS) will also be analyzed s eparately by [CONTACT_11338], site or gender.  
In addition, the primary endpoint (OS) will be analyzed separately by [CONTACT_415179] -US 
region.     
 
   
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Screening Period  The following screening and enr ollment evaluations should be performed  within 14 
days prior to randomization : 
 ICF (before any study required tests are performed),  
 Physical examination,  
 Medical history,  
 Child -Pugh assessment of chronic liver disease  
 Assessment of liver function, inclu ding  presence/a bsence of portal 
hypertension  and normal/a bnormal bilirubin levels  
 ECOG Performance Status assessment  
 Triple -phase spi[INVESTIGATOR_15143] /MRI  to assess liver tumor presentation  and estimate 
tumor burden in the liver.  
 Chest CT /MRI  to rule out extra -hepat ic metastases  
 FACT -Hep quality of life questionnaire  
 Required l aboratory blood work plus α -feto protein  (AFP)  
The date of screening is the date all screening procedures are completed  
Randomization  Upon meeting eligibility for study participation in accordance with the Eligibility  
criteria, p atients will be randomize d 1:1  between the Treatment and Control groups    

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 18 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  In order to balance the treatment groups, patients will be stratified at randomization 
on the basis of Region (North America and Europe vs Asia) , ECOG Performance Status 
(0 vs 1),  presence or absence of bran ch portal vein thrombosis.  
Control Group 
(Sorafenib)  All patients randomized to the Control  group  should start their planned standard -of-
care treatment with sorafenib as soon as possible after randomization .  
Patient s will follow standard dosing for sora fenib according to the product label 
information as prescribed by [CONTACT_093]. Medically appropriate  dose 
adjustments  and drug holidays due to  adverse events and toxicity  are allowable . 
Treatment Group  
(TheraSphere followed 
by [CONTACT_605634])  As soon as possible after randomization, h epatic angiography will be performed to 
assess hepatic vascular anatomy and tumor hypervascularity, followed by a 99mTc-
MAA scan to rule -out gastrointestinal flow or unacceptable lung shunting. 
Embolization may be performed, if necessary, to close off gastrointestinal flow so 
that the patient can  qualify for treatment with TheraSphere . The lobe with the 
highest tumor burden should be scheduled for first treatment with TheraSphere.   
Patients will not be able to receive TheraSp here if the potential radiation dose to the 
lungs exceeds 30 Gy for a single treatment or cumulative 50 Gy or embolization 
cannot be performed to effectively block GI blood flow from the hepatic arterial 
system.  If radiation exposure to the lungs exceeds 3 0 Gy (or 50 Gy cumulative), dose 
reduction of TheraSphere is permitted (minimum dose allowed is 90 Gy ± 10%).  
If after consideration of dose reduction, radiation exposure to the lung continues to 
be greater than 30 Gy (or 50 Gy cumulative), sorafenib trea tment  will be initiated as 
soon as possible and  99mTc -MAA will be repeated after 4 weeks of continuous 
treatment with sorafenib. If radiation exposure to the lung is less than 30Gy for a 
single treatment or 50Gy cumulative w ithin a  target dose of 90 -120 Gy +10%  , the 
patient may commence treatment with TheraSphere. In such instances, sorafenib 
should be discontinued at least [ADDRESS_802050] 2 weeks after the administration of TheraSphere . If 
radiation exposure to the lung  is outside of the permitted range, treatment  with 
sorafenib should be continued.     
In the case where TheraSphere could not be delivered at at target dose of 120 Gy ± 
10% within 28 days of randomization, these  patients wi ll be in cluded in the 
Treatment Group  Intent -to-Treat analysis, but not in the Treatment Group  Per-
Protocol analysis.  
TheraSphere Treatment #1 :  TheraSphere treatment should occur within 28 days of 
randomization , and prior to the initiation of sorafenib . The number of infusions 
required to achieve lobar treatment will be determined by [CONTACT_737], based on 
the hepatic vascular anatomy.   
Patients will receive 120 Gy ± 10% of TheraSphere to the treated lobe of the liver and 
may be administered in multip le infusion s to address vascular abnormalities.   
TheraSphere Treatment #2 :  Patients who have bilobar disease at randomization 
should have TheraSphere administered to the untreated lobe.  If needed, a  second 
angiogram and/or 99mTc-MAA scan should be perfo rmed.   Such treatments typi[INVESTIGATOR_605610]  [ADDRESS_802051] -of-care  
sorafenib treatment in accordance with the sorafenib label directions.  
Re-treatment of the same patient with further cycles of TheraSphere is permitted if a 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802052] approximately every 8 weeks from 
randomization until one of the study discontinuation criteria  is met  (see 9.2.19). The 
following assessments take place at the follow -up visit :  
o ECOG Performance Status assessment  
o Standard laboratory blo od draw for CBC, differential, electrolytes, BUN, 
glucose, liver function test, coagulation panel, and α -fetoprotein biomarker  
o Triple phase spi[INVESTIGATOR_23585] a bdomen  CT/MRI scan  
o Spi[INVESTIGATOR_15143] /MRI  scan  of chest and pelvis  
o Child -Pugh Status  
o QOL questionnaire  
o Adverse event reporting  
 
Patients discontinuing sorafenib treatment in either arm of the study must be 
followed -up for survival until consent is explicitly with drawn or any of the  other 
study completion criteria  is met (see Section 9.2.19).     
Independent Data 
Monitor ing Committee  This study will have oversight by a n Independent Data Monitoring Committee  who  
will meet as determined to review the enrollment, protocol deviations, and safety 
events.  They will evaluate the data at interim analyses for consideration of stop pi[INVESTIGATOR_605611] -estimation at 
the second interim analysis.    The IDMC  will evaluate the final study report . 
 
 
  
   
   
  

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 20 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019   
 
2.0 TRIAL SCHEMA  
 
 

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802053] OF ABBREVIATIONS  
AE - Adverse event  
ADE – Adverse device effect  
AFP – Alphafeto protein  
ALT – Alanine Transaminase  
AST – Aspartate Transaminase  
BUN – Blood Urea Nitrogen  
CBC – Complete Blood Count  
CDR – Central Dosimetry Review  
CRC – Colorectal  Cancer  
Cr - Chromium  
CT – Computed Tomography  
CTCAE – Common Toxicity Criteria for Adverse Events  
DSMB – Data Safety Monitoring Board  
ECOG – Eastern Cooperative Oncology Group  
eCRF – electronic Case Report Form  
FACT -Hep - Functional  Assess ment of Cancer Therapy – Hepatobiliary Questionnaire  
FHSI8 – Functional Assessment of Cancer Therapy – Hepatobiliary Symptom Index 8  
GBq  - gigabecquerel  
GI – gastrointestinal  
Gy – Gray, a measure of irradiation dose  
HCC – Hepatocellular Carcinoma  
HDE – Hum anitarian Device Exemption  
ICF – Informed Consent Form  
IDMC – Independent Data Monitoring Committee  
INR – International Normalized Ratio for prothrombin time  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 25 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  IRB – Institutional Review Board  
LFT – Liver function tests  
MIRD - Medical Internal Radiation Dose  
mITT – Modified Intention -To-Treat  
NCI – National Cancer Institute  
PE – Physical exam  
PFS – Progression Free Survival  
PT - Prothrombin Time  
PTT – Partial Thromboplastin Time  
RECIST – Response Evaluation Criteria in Solid Tumor  
SAE – Serious adverse event  
SADE – Serious adverse device effect  
SOC – Standard -of-care  
99mTc-MAA – Techn etium-99m Magro aggrega ted albumin  
TS - TheraSphere  
TTP – Time -to-Progression  
TTUP – Time -to-Untreatable Progression  
UADE – Unanticipated Adverse Device E ffect  
WBC – White Blood Cel ls 
Y-90 (Y-88, Y -91) – Ytrium -90 and isotopes  
 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 26 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019   
5.0 BACKGROUND AND RATIONALE  
5.1 GENERAL DEVICE DESCRIPTION  
TheraSphere®  (TS) consists of insoluble glass microsphere s in which yttrium -90 (Y-90) is an integral 
component of the glass. The sphere diameter ranges fro m 20 to 30 µm with 22,000 to 73,000 
microspheres per milligram. TheraSphere is available in  dose sizes ranging from 3 – 20 GBq (typi[INVESTIGATOR_897]  
3 GBq, 5  GBq, 7  GBq, 10  GBq, 15  GBq and 20 GBq) each supplied in 0.[ADDRESS_802054].  
Yttrium -90 is a pure beta emitter which decays to stable zirconium -90 with a physical half -life of 64.2 
hours. The average energy of  the beta emissions from yttrium -90 is 0.9367 MeV with mean tissue 
penetration of approximately 2.5 mm.  
TheraSphere is administered through the hepatic artery which supplies blood to tumor tissue (the portal 
vein supplies blood to the normal hepatic tissu e). The microspheres are trapped in the vasculature of the 
tumor due to arteriolar capi[INVESTIGATOR_281382] a local radiotherapeutic effect. In clinical use, 
the glass microspheres remain permanently trapped in the vasculature where the isotope decays to 
infinity leaving background radiation with no therapeutic value.  
5.2 GLOBAL REGULATORY STATUS OF THERA SPHERE  
TheraSphere received a Humanitarian Device Exemption (HDE) from the [LOCATION_002] Food and Drug 
Administration (FDA) in 1999 (HDE H980006) a nd is currently approved for use in radiation treatment or as a 
neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma (HCC) 
who can have placement of appropriately positioned hepatic arterial catheters. The device  is also indicated 
for HCC patients with partial or branch portal vein thrombosis/occlusion, when clinical evaluation warrants 
the treatment. The current US package insert is provided in Appendix  1a. 
TheraSphere is approved for use in Europe for the treatm ent of hepatic neoplasia . TheraSphere is approved  
in Canada for the treatment of hepatic neoplasia in patients who have appropriately positioned arterial 
catheters. In addition, TheraSphere is available  commercially  in Saudi Arabia, Hong Kong, Singapore , S. 
Korea , South Africa , Turkey , Kuwait , Brazil, Argentina and Mexico  for the treatment of hepatic neoplasia.  
The current Canadian  package insert and Instructions for Use in Europe are  provided in Appendix  1b and 1c, 
respectively.  
5.3 RATIONALE FOR THE TREATMENT  OF HEPATOCELLULAR CARCINOMA  
According to th e International Agency for Research on Cancer (IARC)1, primary liver cancer is a major 
health problem worldwide.  Globally, it is the sixth  most commonly diagnosed cancer, with more than 
749,[ADDRESS_802055] leading cause of cancer death in men and sixth among women. 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 27 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  In North America and Western or Northern Europe, areas with historically low rates, the incidence of liver 
cancer is increasing, possibly due to increased prevalence of hepatitis  C.  
In 2007, the FDA2 approved sorafenib tosylate  (Nexavar®), a small molecule Raf kinase and VEGF receptor 
kinase inhibitor , for the treatment of patients with unresectable  hepatocellular carcinoma (HCC).  
The approval was  based on the results of an international, multicenter, randomized, double -blind, 
placebo -controlled trial (SHARP3 trial) in patients with unresectable, biopsy -proven hepatocellular 
carcinoma.  Overall survival was the primary efficacy endpoint. A total of  602 patients were randomized; 
299 to sorafenib 400 mg twice daily and 303 to matching placebo.  
Demographics and baseline disease characteristics were similar between the sorafenib and placebo 
group s. Prior treatments included surgical resections (20 perce nt), locoregional therapi[INVESTIGATOR_014] (including 
radiofrequency ablation , percutaneous ethanol injection  and transarterial chemoembolization  in 40 
percent), radiotherapy (5 percent), and systemic therapy (4 percent) . 
The trial was stopped following a pre -specified second interim analysis for survival disclosing a statistically 
significant  advantage for sorafenib [m edian 10.7 vs. 7.9 months; HR: 0.69 (95 percent CI: 0.55, 0.87), p= 
0.[ZIP_CODE]]. The final analysis of time -to-tumor progression (TTP) by [CONTACT_605635] a statistically significant  improvement in TTP 
in the sorafenib group  [median 5.5 vs. 2.8 months; HR: 0.58 (95 percent CI: 0.45, 0.74),  p=0.000007].  
Sorafenib is  now suggested as the standard -of-care (SOC)  therapy4  for patients with advanced HCC, the 
patients classified as BCLC C a ccording to the Barcelona Clinic Liver Cancer (BCLC) classification system.    
Sorafenib is in cluded in the NCCN Clinical Practice Guidelines in Oncology5  (NCCN – Hepatobiliary cancers 
V.1.2010 – HCC5) as one of the possible treatments for patients with un resectable HCC and extensive liver 
disease who are not candidates for transplantation.  
Although s orafenib is a SOC in the treatment of patients with HCC, it is associated with only a modest 
improvement in median survival as compared to b est supportive care .  Further, s orafenib treatment is 
associated with significant toxicity. The most common adverse reactions14 (≥20 percent) considered 
related to sorafenib were fatigue, weight loss, rash/ desquamation, hand -foot skin reaction, alopecia, 
diarrhea, anorexia, nausea and abdominal pain. Diarrhea was reported in 55 percent of sorafenib patients 
(grade 3 in 10 percent) . Hand -foot syndrome (21 percent overall; grade 3 in 8 percent) and rash (19 
percent overall; grade 3 in 1 percent) were the most common dermatologic adverse reactions to 
sorafenib.  Sorafenib dose reductions and drug holidays are often required  to manage these toxicities .   
Subsequent subset analysis of the SHARP trial data6 indicate d that the efficacy of s orafenib is reduced in 
an important subset of patients with advanced HCC.  In patients with extrahepatic spread or macroscopic 
vascular invasion, the me dian survival was 8.9 months in patients treated with sorafenib as compared to 
6.7 months in patients treated with placebo.  
Salem et al7  recently published their long -term experience of TheraSphere in the treatment of patients 
with HCC. In this report, p atients with HCC (n=291) were treated with TheraSphere  as part of a single -
center, prospective, longitudinal cohort study. Toxicities were recorded using the Common Terminology 
Criteria version 3.0. Response rate and time to progression (TTP) were determin ed using World Health 
Organization (WHO) and European Association for the Study of the Liver (EASL) guidelines. Survival by 
[CONTACT_605636]. Univariate/multivariate analyses were performed. A total of 526 treatments were 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 28 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  administered (mean, 1.8; range, 1-5). Toxicities included fatigue (57%), pain (23%), and nausea/vomiting 
(20%); 19% exhibited grade 3/4 bilirubin toxicity. The 30 -day mortality rate was 3%. Response rates were 
42% and 57% based on WHO and EASL criteria, respectively. The overall median TTP was 7.9 months (95% 
confidence interval, 6 -10.3). Median s urvival times differed between patients with Child -Pugh A and B 
disease (A, 17.2 months; B, 7.7 months; P = .002). Patients with Child -Pugh B disease who had portal vein 
thrombosis (PVT) had a me dian surviv al of  5.6 months (95% confidence interval, 4.5 -6.7). Baseline age; 
gender ; performance status; presence of portal hypertension; tumor distribution; levels of bilirubin, 
albumin, and alpha -fetoprotein; and WHO/EASL response rate predicted surviva l. These investigators 
concluded that patients with Child -Pugh A disease, with or without PVT, benefited most from treatment. 
Patients with Child -Pugh B disease who had PVT had poor outcomes. TTP and overall survival varied by 
[CONTACT_281402].  
Hilgard8 et al report treatment of [ADDRESS_802056] in 62 patients were complete 
or partial response 10 (16%), stable disease 46 (74%) and progressive disease 6 (10%). Toxicities were 
generally mild to moderate with the most common being transient fatigue during the week following 
administrati on (61%) and abdominal pain (56%). One case of radiation cholecystitis was treated with 
cholecys temtomy . There was no Grade 3 or 4 lung toxicities. Lymphopenia was observed without clinical 
sequellae. Because hepatic decompensation is a known risk of yttri um-90 microsphere therapy, all 
elevations in bilirubin values were considered to be treatment related hepatotoxicties. For patients with 
normal bilirubin at enrollment, 32% experienced Grade 1 or 2 elevations and three patients developed 
Grade 3 elevations . For patients with elevated bilirubin at enrollment, 17% experienced Grade 2 
elevations and 30% experienced Grade 3 or 4 elevations. In the majority of patients, bilirubin returned to 
baseline values within 4 -6 weeks. The authors conclude the therapy is s afe and effective, even in patients 
with compromised liver function.  
At the International Liver Cancer Association conference in September 2010, Metrakos9 et al reported 
preliminary results of a Phase II investigation of the safety, tolerability and effic acy of administering 
TheraSphere and Nexavar (sorafenib) treatment in patients with HCC. In this trial, all patients (N=26) 
began sorafenib [ADDRESS_802057] p atients (65%) required sorafenib dosage adjustment. The 
most common toxicities were diarrhea, fatigue and hand foot syndrome with most being self -limiting and 
responsive to dose adjustment.  One single grade 4 toxicity of worsening cirrhosis was observed. Median 
survival is 15.5 months which exceeds that reported in the sorafenib or placebo arms of the SHARP study 
(10.7 and 7.9 months respectively). The reported toxicities are consistent with the toxicity profile of both 
TheraSphere and sorafenib with no ap parent increase in severity or frequency.  
As illustrated by [CONTACT_605637], there is now an extensive clinical experience demonstrating the 
safety of  TheraSphere in the management of patients with unresectable HCC.  
The early reports of serious ad verse events possibly associated with the use of TheraSphere included death, 
hepatorenal failure, liver abscess, hepatic encephalopathy, hepatic decompensation, radiation hepatitis, 
radiation pneumonitis, duodenal ulcer, gastrointestinal bleeding and chole cystitis. As clinical experience 
with TheraSphere increased, the pre-treatment high risk factors associated with these early serious events 
were identified, leading to  improved patient selection criteria and thereby [CONTACT_605638]. These risk factors include infiltrative tumor type, bulk disease (tumor volume >70% or nodules 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 29 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  too numerous to count), AST or ALT > five times the upper limit of normal, bilirubin > 2 mg/dL, tumor 
volume >50% in the presence of an albumin < 3 g/dL and  those in whom extra -hepatic shunting to the lungs 
or gastrointestinal tract cannot be managed through standard angiographic techniques.  
For those patients without the pre -treatment high risk factors noted above, TheraSphere is very well 
tolerated , with treatment in the US commonly administered in an outpatient setting .   Hospi[INVESTIGATOR_605612]. The most commonly reported adverse 
events associated with TheraSphere administration are fatigue, abdominal pain, nausea/vomiting and 
transient laboratory values including elevated bilirubin, AST, ALT, alkaline phosphatase, decreased platelets 
and lymphocyte depression with no clinical sequelae.  
In this trial, all patients with unresectable HCC eligibl e for treatment with SOC sorafenib may be 
considered for study participat ion.  Patients  who meet the entry criteria will be randomized to either the 
patient’s planned SOC sorafenib therapy  (Control  group), or to TheraSphere administered prior to  the 
patien t’s SOC sorafenib therapy (Treatment group).  The primary outcome measure for this trial is overall 
survival.   
Our outcome assumption in the Control  group  is based on the SHARP trial, with a median overall survival 
of 10.7 months for patients treat ed with sorafenib.  We assume a  median overall survival of 14.2 months 
in the Treatment  group , (hazard ratio = 0.7 54).  However, d ue to uncertainty in the expected treatment 
effect, a sample size re -estimation is planned, which would allow the sample size to incre ase in order to 
detect a smaller  increase in median OS time, from 10.7  months in the sorafenib arm to 13.7 months in the 
TheraSphere arm (ie, hazard ratio = 0.7 81).  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.0 STUDY OBJECTIVE  
The objective of this clinical study is to evalu ate TheraSphere in the treatment of patients with 
unresectable hepatocellular carcinoma .  

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802058] meet all eligibility  criteria:  
1. Must have signed informed consent prior to any study -related evaluation  
2. Must be male or female patients o ver [ADDRESS_802059] 
or MRI (according to RECIST  1.1) 
5. Must have a Child Pugh sc ore ≤ [ADDRESS_802060] an ECOG Performance Status score of ≤ [ADDRESS_802061] Platelet count > 50 x 109/L or > 50% prothrombin activity  
10. Must have Hemoglobin ≥ 8 .5 g/dL 
11. Must have Bilirubin  ≤  2.5 mg/dL  
12. ALT and AST must be < 5X upper limit of normal  
13. Amylase or lipase must be ≤ 2X upper limit of normal  
14. Serum creatinine must be ≤ 1.5X upper limit of normal  
15. INR must be ≤ 2.[ADDRESS_802062] main PVT  (branch portal vein thro mbosis is permissible)  
17. Must not be  eligible for curative treatment ( e.g ablation or transplantation)  
18. Must not have a history of previous or concurrent cancer other than HCC unless treated 
curatively [ADDRESS_802063] confirmed p resence of extra -hepatic disease with the exception of  lung nod ules 
and mesenteric or portal lymph  nodes ≤ 2. [ADDRESS_802064] not be at risk of hepatic or renal failure  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802065] tumor replacement >70% of total liver volume based on visual estimation by [CONTACT_605639] >50% of total liver volume in the presence of  
albumin <3 g/dL  
22. Must not have any  history of severe allergy or intolerance to contrast agents, narcotics sedatives 
or atropi[INVESTIGATOR_605608]  
23. Must not have any contraindications to angiography and selective visceral catheterization  
24. Must not have history of organ allograft  
25. Must not have any known contraindications to sorafenib  including allergic reaction, pi[INVESTIGATOR_4382] -
swallowing difficulty,  evidence of severe or uncontrolled systemic diseases , uncontrolled  severe  
hypertension or cardiac  arrhythmi as, congestive cardiac failure >[LOCATION_001] Heart Association  
(NYHA)  class 2, myocardial infarct within 6 months, prolonged QT/QTc >450ms,  evidence of 
torsades de pointe,   or laboratory finding that in the view of the investigator makes it 
undesirable for the  patient to participate in the trial  , significant GI bleed within [ADDRESS_802066] not  be taking any of the following: Rifampi[INVESTIGATOR_2513], St. John’s Wort, phenytoin, carbamazepi[INVESTIGATOR_050], 
phenobarbital, and dex amethasone  
27. Must  not  be taking a ny other systemic anticancer  agent ( e.g docetaxel, doxorubicin, irinotecan  
etc. ) 
28. Must not be taking  substrate agents for CYP2B6 (buproprion, cyclophosphamide, efavirenz, 
ifosfamide, methadone, pacilitaxel, amodiaquine, repa glinide)  
29. Must not be taking  UGT 1A1 and UGT 1A9 substrates (e.g., irinotecan)  
30. Must not be taking P -Gp substrates (e.g., Digoxin)  
31. Any prior liver resection must have taken place > 2 months prior to randomization  
32. Treatment with other locoregional therapi[INVESTIGATOR_014] ( other than study treatment) has not been planned 
for the duration of the clinical study period  
33. Has not received any prior external beam radiation treatment to the  chest,  liver or abdomen  
34. Has not received any prior yttrium -90 microsphere treatment to the l iver 
35. Prior treatment with transarterial chemoembolization (TACE) or bland embolization must have 
occurred > [ADDRESS_802067] been applied to a treatment field 
and/or lobe that is not to be treated under this protocol . For patie nts with tumor progression in 
the treatment field and/or lobe previously treated with TA(C)E, vessels feeding the tumor(s) must 
be assessed for adequate blood flow using angiography (cone beam computerized tomography 
(CBCT) strongly recommended), and the T ACE or bland embolization must have been applied >[ADDRESS_802068] due to prior t herapy that is unresolved at randomization  
38. Has not received any prior systemic therapy for the treatment of HCC, including sorafenib  given 
for more than 4 weeks during the 2 previous months prior to randomi zation; no prior sorafenib 
related toxicity  
39. No ev idence of pulmonary insufficiency or  inadequately treated moderate grade or severe/very 
severe grade  chronic obstructive pulmonary disease  
40. Must not have undergone any intervention for, or compromise of, the Ampulla of Vater  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802069] any clinically ev ident ascites (trace ascites on imaging is acceptable)  
42. Must not be pregnant or breast -feeding  
43. Women of childbearing potential must have a negative serum pregnancy test within  [ADDRESS_802070] n ot be participating in concurrent clinical trials evaluating treatment intervention(s).  
9.[ADDRESS_802071] after the screening/ randomization period should occur within 
+/- 14 days of the designated time interval for that study visit.  
9.1.1  SCREENING /RANDOMIZATION (DAYS -14 TO DAY 0) 
All screening an d baseline evaluations must be completed within [ADDRESS_802072]/MRI  
scans obtained for clinical management within [ADDRESS_802073] be signed (as described in Section 13.7 . 
2. Patient demographic information will be collected as described in Section 9.2.2 . 
3. Medical History information will be collecte d as described in Section 9.2.3 . 
4. A physical examination as described in Section 9.2.4  will be done . 
5. ECOG Performance Status will be assessed as described in Section 9.2.5 . 
6. Medication history  & Prior treatment history will be obtained as described in Section 9.2.[ADDRESS_802074]  as described in Section  9.2.10  will be administered for all female patients 
of childbearing potential.  
11. The patient’s eligibility to participate will be assessed as described in Section 9.2.11 . 
12. A baseline AFP level will be drawn.  
13. Baseline images fo r efficacy evaluation ( Spi[INVESTIGATOR_605613]/pelvis and Spi[INVESTIGATOR_605614] ) will 
be taken  as described in Section  9.2.16 . 
14. Baseline Quality of Life assessments will be made as described in Section 9.2.13 . 
 
Following Screening, patients meeting the eligibility  criteria will be randomized as described in Section 
9.2.14 .  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 33 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  The date of screening is the date all screening procedures are completed  
9.1.2  PATIENTS RANDOMIZED T O THE CONTRO L GROUP  
[IP_ADDRESS]   WEEKS 1-4 FOLLOWING RANDOMIZATION  – CONTROL  GROUP  
The following clinical patient management activities will be completed  as appropriate  and documented on 
the electronic case report forms .  Patients may need several visits during this period to adj ust the dose of 
sorafenib.  
1. If treatment with sorafenib commences greater than 14 days after randomization , , complete 
appropriate clinical laboratory tests, including AFP, prior to treatment  as described in Section 0. 
2. Admi nister SOC sorafenib in Control  Group  as described in Section  [IP_ADDRESS] . 
3. Record details on the clinical assessments and  administration of sorafenib . 
4. Record any treatment and concurrent medications and any adverse events as descr ibed in 
Section s 9.2.18 , 9.2.19  and 12.2 . 
 
[IP_ADDRESS]  Q 8 WEEKS FOLLOWING RANDOMIZATION – CONTROL  GROUP  
In addition to the administration of sorafenib and the evaluations associate d with that therapy, at  every 8 
week visit  following randomization, the following will be completed:  
 
1. Clinical laboratory tests  as described in Section 0. 
2. CT/MR images will be taken as described in Section  9.2.[ADDRESS_802075] until death.  
 
9.1.3  PATIENTS RANDOMIZED T O THE TREATMENT GROUP  
[IP_ADDRESS]  WEEKS 1-4 FOLLOWING RANDOMIZATION – TREATMENT GROUP  
   The following clinical patient management activities will be completed  and documented on the 
electronic case report forms  (eCRF) : 
1. If treatment commences greater than [ADDRESS_802076] TheraSphere pre-treatment  evaluation s and administer TheraSphere in Treatment 
Group as described in Section [IP_ADDRESS] . 
3. Record details on the clinical assessments and  administration of TheraSphere  
4. Record any treatment and concurrent medications and any adverse events as described in 
Section s 9.2.18 , 9.2.19  and 12.2 . 
 
[IP_ADDRESS]  WEEKS 5-8 FOLLOWING RANDOMIZATION  – TREATMENT GROUP  
The following clinical patient management activities  will take pla ce and wil l be documented on the eCRF : 
1. Complete appropriate clinical laboratory tests  as described in Section 0. 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 34 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  2. Administer TheraSphere as described in Section [IP_ADDRESS].[ADDRESS_802077] any treatments and concurrent medications and any adverse events as described in 
Section s 9.2.18 , 9.2.19  and 12.2 . 
[IP_ADDRESS]  >2 & <[ADDRESS_802078]  and will be documented on the eCRF : 
1. Adminis ter SOC sorafenib  in Treatment Group  as described in Section  [IP_ADDRESS] . 
2. Record details on the clinical assessments and  administration of sorafenib.  
3. Record any concurrent medications and any adverse events as described in Section s 9.2.18 , 
9.2.19  and 12.2 . 
[IP_ADDRESS]  THERA SPHERE RE-TREATMENT  AFTER HEPATIC PROGRESSION – TREATMENT GROUP  
Additional TheraSphere treatments may be administered after hepatic progr ession if the lesions are 
amenable to treatment. The following activities will take place:  
1. Complete appropriate clinical laboratory tests, as described in Section 0. 
2. Conduct TheraSphere pre-treatment  evaluation s and adminis ter TheraSphere in Treatment 
Group as described in Section [IP_ADDRESS] . 
3. Record details on the clinical assessments and  administration of TheraSphere  
4. Record any treatment and concurrent medications and any adverse events as describ ed in 
Section s 9.2.18 , 9.2.19  and 12.2 . 
[IP_ADDRESS]  Q 8 WEEKS  FOLLOWING RANDOMIZATION  – TREATMENT GROUP  
In addition to the administration of SOC sorafenib and the evaluations associ ated with that therapy, at  
every 8 week visit  following randomization, the following will be completed:  
1. Clinical laboratory tests  as described in Section 0. 
2. CT/MR images will be taken (as described in Section  9.2.16 ) for efficacy assessment.  
3. Quality of Life assessments will be obtained as described in Section 9.2.[ADDRESS_802079] until death.  
 
9.1.4  PATIENT COMPLETION OR EARLY WITHDRAWAL  
If a patient completes the trial or withdraws early, the following activities will be completed  as 
appropriate : 
1. Record the date and reason for study exit, as described in section 9.2.[ADDRESS_802080]/MR images , as appropriate,  for efficacy assessment.  
6. Complete the Quality of Life assessments , as appropriate, as described in Section 9.2.13 . 
 
 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802081] the opportunity to ask the Investigator any questions regarding the trial, and their  rights and 
obligations as a trial participant before any protocol related evaluations can be performed. The details 
regarding informed consent are described in Section 13.7 . 
9.2.2  DEMOGRAPHICS   
Demographic data (age, gender, female childbearing potential, race, and ethnicity) will be obtained.  
9.2.3  MEDICAL HISTORY  
Medical history deemed clinically significant by [CONTACT_605640] 
(allergy/immunology, auditory/ear, blood/bone marrow, cardiac arrhythmia, ca rdiac general, 
dermatology/skin, endocrine metabolic, gastrointestinal, hemorrhage/bleeding, Hepatobiliary/pancreatic, 
infection, musculoskeletal/soft tissue, neurologic, ocular/vision, psychiatric, pulmonary/upper respi[INVESTIGATOR_696], 
renal/genitourinary, sexual reproductive function, vascular).   
The d iagnoses and history  of HCC  will be recorded separa tely from other medical history and will include 
assessment of liver function, including Child -Pugh assessment of chronic liver disease, and presence of 
portal hyper tension.  
All on -going medi cal conditions and adverse events arising from treatment of those conditions present for 
≥ 30 days are generally considered a part of the patient’s medical history and must be recorded at 
baseline.    
9.2.4  PHYSICAL EXAMINATION  
A physic al examination will also be performed, which will cover the following:  
 Vital signs:  heart rate ( HR), respi[INVESTIGATOR_697] ( RR), blood pressure ( BP) taken after sitting for 5 
minutes,  and temperature  (T) 
 Height and weight  
 Head, eyes, ears, nose, and throat  
 Chest 
 Heart  
 Abdomen  
 Extremities  
 Brief neurological examination (level of consciousness, orientation, sensation, and motor 
function)  
 Genitourinary, endocrine and allergy/immunology systems  
9.2.5  ECOG  PERFORMANCE STATUS  
ECOG Performance Status11 will be assessed accor ding to the following categories:  
Score  Characteristics  
0 Asymptomatic and fully active  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 36 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  1 Symptomatic; fully ambulatory; restricted in physically strenuous activity  
2 Symptomatic; ambulatory; capable of self -care; more than 50% of waking hours 
are spent  out of bed.  
3 Symptomatic; limited self -care; more than 50% of waking hours are spent in bed  
4 Completely disabled; no self -care; bedridden.  
 
9.2.6  CHILD-PUGH SCORE STATUS  
Severity of liver disease will be assessed according to the Child -Pugh classification of Severity of Liver 
Disease (see Appendix 4) at screening and at every 8 weeks visit.  
9.2.7  MEDICATION AND PRIOR TREATMENT HISTORY  
The use of prior and concurrent medications (medications taken within [ADDRESS_802082] of the study  respectively ) will be obtained and documented on the relevant eCRF. Palliative 
medications and/or HCC treatments administered for patients discontinuing sorafenib must also be 
documented.   
Prior treatments  for HCC  will be recorded separately from treatment f or other medical conditions.  
The start and stop dates for all such prior treatments for HCC or other cancer treatments as well as prior 
treatment of other medical conditions should be recorded.  
9.2.[ADDRESS_802083] will be drawn 
and the respective lobar and tumor volumes determined  (a detailed discussion begins on page 1259 in 
Appendix 2).  
Tumor replacement, expressed as a per cent  of total liver volum e, will be recorded on the relevant eCRF.  
9.2.[ADDRESS_802084] be 
documented as described in Section 13.4 . Laboratory assessme nts undertaken as part of SOC clinical 
assessment may be used.  
 Hematology:  complete  blood c ell count  (cBC) ,  differential white blood count (WBC) , platelet 
count, hematocrit, hemoglobin,  
 Coagulation: Prothrombin Time (PT), Partial Thromboplastin Time (PT T), International 
Normalized ratio  for prothrombin time (INR)  
 Chemistry panel: serum creatinine, blood urea nitrogen (BUN), glucose, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), albumin,  amylase, lipase,  total bilirubin, 
and alkaline p hosphatase.  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 37 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019   Alpha -fetoprotein ( AFP) 
9.2.[ADDRESS_802085] 
eligibility  criteria to determine eligibility. The determination will be recorded on the relevant case report 
form ( eCRF). 
9.2.12  HCC  TUMOR BIOMARKER  
Blood will be collected prior to and at the 8 weeks study visits following randomization to  determine the 
baseline and subsequent AFP values.   
9.2.13  QUALITY OF LIFE 
Functional Assessment of cancer Therapy – Hepatobiliary Questionnaire ( FACT -HEP) quality of life 
instrument s suitable for patients being treated for hepatocellular carcinoma  will be admin istered at study 
visits every [ADDRESS_802086] treatment in either group is  administered.  
9.2.14  RANDOMIZATION (STUDY DAY 0) 
Patients w ill be randomized 1:[ADDRESS_802087] identity code 
consisting of the protocol number, the country code (e.g.01), the site number (e .g. 01) and a patient 
number ( e.g. 001) .   
In order to create a balance between study group s, patients will be stratified at randomization based on 
the following:  
 Region (North America and Europe versus Asia)  
 ECOG performance status (0 vs 1)  
 Presence or absence of branch portal vein t hrombosis  
Patients randomized to the Control  group  or the Treatment  group who are unable to receive their 
planned study treatment will continue to be followed under their assigned study group  for the purpose of 
the intent -to-treat analysis.  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 38 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  If a patient is  found ineligible for the study,  the patient will not be randomized and the reason for 
treatment ineligibility  should be documented on the Screen Failure Log.   
9.2.15  STUDY TREATMENTS  
[IP_ADDRESS]  THERA SPHERE  
TheraSphere will be administered to the disease d lobes  present at randomization , before initiation of the 
SOC sorafenib treatment . Patients with unilobar disease will receive treatment of the diseased lobe. 
Patients with bilobar disease will have the second procedure visit such that the second administration 
occurs withi n Weeks [ADDRESS_802088] two (2) weeks after the administration of 
TheraSphere is completed.  Generally, patients should initiate SOC sorafenib  between [ADDRESS_802089] 2 weeks prior to initiating sorafenib therapy to allow decay of the 
radioactive microspheres and recover y from the expected transient adverse effects (fatigue, abdominal 
pain, nausea/vomiting)  associated with TheraSphere administration . Ideally , SOC sorafenib should  be 
started no later than [ADDRESS_802090] demonstrated hepatic progression with 
hepatic lesions amenable to TheraSphere, re-treatment  with TheraSphere is allowed. Sorafenib will be 
discontinued seven (7) days prior to TheraSphere treatment (equivalent to approxi mately five  to seven  
half-lives)  through 2 weeks  after TheraSphere treatment to permit radioactive decay and patient recovery 
from transient side effects.  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 39 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  [IP_ADDRESS].[ADDRESS_802091] undergo the fo llowing evaluation s to determine 
eligibility to receive the TheraSphere . These  are described in detail in Appendix 2, pages 1254 -1255 and 
include:  
 Hepatic Angiography : selective celiac and superior mesenteric arteriograms are needed to 
evaluate the hepatic  arterial anatomy for the whole liver, as well as evaluation of potential 
sources of extra -hepatic blood supply to tumors.  The goal is to identify, within the hepatic 
vascular anatomy, a catheter placement location that allows a single TS infusion through out the 
lobar tumor volume without administration of microspheres to extra -hepatic structures.   
 A technetiu m-99m macroaggregated albumin (99mTc-MAA) scan is used to assess the potential for 
shunting microspheres to the lungs as well as the potential for t he deposition of microspheres to 
the gastrointestinal (GI) tract . Repeat 99mTc-MAA may be needed  for subsequent treatments  to 
estimate cumulative lung shunt or re -asses GI flow.    Note that 3 technical factors, as discussed in 
Appendix 2 (time between admi nistration of 99mTc-MAA  and the scan, 99mTc-MAA  particle size 
and the presence of free 99mTc-MAA ) can lead to an over -estimation of shunting to the lungs and 
should be controlled.  
TheraSphere should not be administered to a patient randomized to the Treatm ent group  if: 
 Deposition of microspheres to the GI tract that cannot be corrected by [CONTACT_605641], such as coil 
embol ization to prevent deposition of microsphe res in the GI tract.  
 
 Exposure  of radiation to the lungs of 30 Gray (Gy) for a single infusion or a cumulative 50 Gy limit 
for all infusions of TheraSphere - estimated during TheraSphere dose calculation as described in 
Section [IP_ADDRESS].3  
 
In the event that the patient is determined not to be suitable and/or cannot be  safely  treated with 
TheraSphere, that patient may proceed to treatment with the planned SOC sorafenib  regimen  as 
described in Section [IP_ADDRESS] .  
[IP_ADDRESS].2  THERA SPHERE ADMINISTRATION STRATEGY  
For patients eligible to receive TheraSphere, the administration strategy (choice of artery position to 
infuse the target vascular bed; selection of placement of coil embolization or other techniques used to 
prevent microsphere deposition to the GI tract) should be determined as discussed in Appendix 2, pages 
[ADDRESS_802092] and calculating lobar volumes, it is the middl e hepatic vein that 
should be used as the anatomic delineator between the right and left lobes.  If the middle hepatic vein 
cannot be seen, then the gallbladder and its axis relative to the liver can be used.  This technique assumes 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802093] for lobar or segmenta l lobar volumes.  This will 
ensure that accurate volumes are obtained and three  or more infusions are administered.  The volume 
that needs to be used for Y -90 dosimetry is that volume of liver that is perfused by [CONTACT_605642].   Target li ver mass is determined by [CONTACT_605643] (segments) infused.  Since there is considerable individual 
variation in hepatic vascular anatomy, the determination of target liver mass will depend on the variant 
encountered.  The Table below presents the most commonly encountered variants with the 
corresponding segments associated to them.   
STANDARD  AND  VARIANT  HEPATIC  VASCULAR  ANATOMY  AND  CORRESPONDING  
COUINAUD  SEGMENTS  
Hepatic Va scular Anatomya: Angiographic 
Findings  Target Segments 
– Infusion 1b Target Segments 
– Infusion 2  Target Segments –
Additional 
Infusion  
Standard right and left hepatic arteries  1, 5, 6, 7, 8  2, 3, 4   
Replaced right hepatic with flow to medial 
segment lef t lobe  1, 4, 5, 6, 7, 8  2, 3  
Replaced right hepatic artery without flow to 
middle lobe, left hepatic artery with flow to medial 
and lateral segments left lobe  1, 5, 6, 7, 8  2, 3, 4   
Replaced left hepatic artery  without flow to 
medial lobe  1, 4, 5, 6, 7,  8 2, 3  
Replaced left hepatic artery  with flow to medial 
lobe 1, 5, 6, 7, 8  2, 3, 4   
Accessory right hepatic artery  6, 7 2, 3, 4  1, 5, 8  
Right hepatic artery in the presence of an 
accessory right hepatic  5, 8 2, 3, 4  1, 6, 7  
Middle hepatic artery  (irrespective of origin)  1, 5 ,6, 7, 8  4 2, 3 
Notes:  
a) vascular anatomy subject to variation  
b) assumes caudate lobe (segment 1) derives blood supply from right hepatic artery  
c) caudate lobe (segment 1), right anterior lobe (segments 5/8), right posterior l obe 
(segments 6/7), left medial lobe (4), left lateral lobe (2, 3)  
[IP_ADDRESS].[ADDRESS_802094] requiring use of angiographic occlusion 
techniques and to determine the lung shunt fraction . The target dose is 120 Gy ± 10%.  If radiation 
exposure to the lungs exceeds 30 Gy (or 50 Gy cumulative), dose reducti on of TheraSphere is permitted to 
a minimum dose of 90 Gy ± 10% .  
If after consideration of dose reduction, radiation exposure to the lung continues to be greater than 30 Gy 
(or 50 Gy cumulative), sorafenib treatment will be initiated as soon as possible and  99mTc -MAA will be 
repeated after 4 weeks of continuous treatment with sorafenib. If radiation exposure to the lung is less 
than 30Gy for a single treatment (or 50  Gy cumulative ) within a  target dose of 90 -120 Gy +10%  , the 
patient may commence treatment with TheraSphere. In such instanc es, sorafenib should be discontinued 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802095] 2 weeks after the 
administration of TheraSphere. If radiation exposure to the lung is outside of the permitted range, 
treatment  w ith sor afenib should be continued. Calculation of Lung Shunt Factor :  Lung shunt factor is 
determined from the 99mTc-MAA  scan using the following equation:  Lung shunt Fraction (F) = total lung 
counts/(total lung+ liver counts)  
Calculation of Target Liver Mass  (kg): Convert the target liver volume to mass assuming a conversion 
factor of 0.00103kg /cm3.   
 
Calculation of Activity required to deliver the desired dose of 120 G y: 
The amount of radioactivity required to deliver the desired target dose (120 Gy) to  the selected liver 
target , adjusted for the estimated fraction that will be shunted to the lung, is calculated using the 
following formula:  
Activity Required (GBq) = [ Desired Dose  (Gy)] [Mass of Selected Liver Target (kg )]  
50[1-F] 
Calculation of estimat ed lung radiation exposure (Gy) : 
  Lung Dose (Gy) per infusion = 50 * Calculated Activity in gigabecquerel  (GBq) * F  
Cumulative exposure is the sum of estimated exposure per infusion for all planned infusions.  
 
[IP_ADDRESS].4  THERA SPHERE DOSE VIAL SELECTION  
Selection of the dose vial size to supply the  required activity (GBq) for delivery of the desired target dose 
to the  selected  target liver volume via the selected vascular route  is dependent on the day and time of the 
scheduled patient treatment and must account for th e time zone in which the hospi[INVESTIGATOR_605615]. The impact of time for available dose sizes is illustrated in the decay 
curve below.  
The TheraSphere Treatment Window Illustrator can be used to select the appropriate d ose vial or 
combination of dose vial(s) required to deliver the calculated activity required.  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 42 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  
 
[IP_ADDRESS].[ADDRESS_802096] dose vial sizes (3 GBq, 
5GBq, 7GBq, 10 GBq, 15GBq and 20GBq) a re made to stock and can be ordered at anytime. Orders for 
custom size dose vials must be received at TheraSphere Customer Services by 12 noon Eastern Time    on 
the Tuesday before the desired Calibration Date  (approximately Day  7-[ADDRESS_802097] -randomization ). 
TheraSphere will be delivered to the institution’s designated radioph armacy and handled according to 
institutional practices .  
Each vial of TheraSphere will be shipped with a packing slip, a copy of which must be transferred to the 
study coordinator for dev ice accountability so that the vials used can be tracked to the specific infusion(s) 
for each patient.  Disposal of used or any unused vials will be handled in accordance with hospi[INVESTIGATOR_605616].  
[IP_ADDRESS].6  THERA SPHERE ADMINISTRATION  
TheraSphere will be administered at a dose of 120 + 10% Gy to each lobe of the liver administered in one 
or more lobar administrations on separate days at least [ADDRESS_802098] hepatic progression wit h hepatic lesions that are still amenable 
to TheraSphere are eligible for re -treatment with TheraSphere.  In these cases, TheraSphere may  be 
administered at the investigator’s discretion using lobar infusions on separate treatment days . If such a 
patient i s being treated with sorafenib , sorafenib therapy should be discontinued  at least  seven (7) days 
prior through 2 weeks after hours after TheraSphere administration . 
TheraSphere should be administered by [CONTACT_605644] e 
departments of Radiology, Nuclear Medicine, and/or Interventional Radiology.  
TheraSphere administration is generally considered to be an outpatient procedure in the [LOCATION_002]. It 
is generally considered to be an inpatient procedure in Europe. The phy sical location for after -care and 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802099] performs this procedure.  The patency of the 
catheter is maintained by [CONTACT_605645] a coagulation inhibitor (per institutional 
protocols) administered via a continuous infusion pump. Prope r catheter positioning in the selected 
location in the hepatic artery will be verified on angiography before TheraSphere administration.  
Standard medication protocol for sedation, pain and infection prophylaxis should be implemented per 
established instit utional protocols. Prophylaxis with a gastric inhibitor (H2 blocker) is recommended to 
minimize risk of post -treatment gastrointestinal side effects.  Although recommended for all patients 
undergoing treatment, this prophylaxis is especially important for patients undergoing TheraSphere 
treatment to the left lobe of the liver, due to the proximity of the gastrointestinal organs, and for patients 
with a prior history of peptic ulcer disease.  Therapy should begin on the day of TheraSphere treatment 
and conti nue for 14 -21 days following each TheraSphere treatment.  
The TheraSphere labeling documents  (Appendix 1 ) describes the specific procedure used to administer 
TheraSphere.   
[IP_ADDRESS].[ADDRESS_802100] should be performed within 48 hours of administration.  
Using institutional practices, the activity of each vial of TheraSph ere will be determined prior to 
administration. This activity will be used to calculate the actual dose delivered to the liver and lung which 
will be recorded on the appropriate eCRF. 
 
Calculation of the liver dose (Gy) delivered : 
Calculation of the delive red dose per  infusion takes into account the activity lost to lung shunting plus 
activity associated with residual microspheres in the administration system and is provided by [CONTACT_605646]:  
 
Dose (Gy) =  50[Injected Activity (GBq)][1 -F][1-R] 
Mass of Selected Liver Target (kg)  
where  F = lung shunt fraction  (determined in Section 9.2. 14.1 .3) 
R = residual fraction (1-fraction of microspheres delivered)  
Calculation of residual activity fraction for microspheres:  
The fraction of microspheres remaining in the device  is calculated using the following formula:  
R =  (W-b’) 
(I-b) 
where  R  = residual activity fraction  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 44 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  b = background dose rate prior to source vial measurement  
I = measured dose rate of source vial positioned greater than 30 cm from ionization c hamber (or 
other measuring device)  
b’ = background dose rate prior to waste measurement and W = average dose rate of shielded 
waste container (containing discarded vial, microcatheter, tubing) positioned with center in same 
location as I  
 
Calculation of Ac tual Lung Radiation Exposure:  
Calculation of the lung dose (Gy) delivered in each infusion is provided by [CONTACT_51632]:  
Lung dose (Gy) = 50* activity delivered (GBq)*F  
[IP_ADDRESS].[ADDRESS_802101] to the policies and procedures dic tated 
by [CONTACT_605647].  Prophylactic treatment 
using gastric inhibitor (H2 blocker) should continue for 14 – [ADDRESS_802102] treatment. In addition, steroids 
(e.g., Medrol Dose Pack) may be take n (with food) over the first six days post -treatment.  
Prior to discharge, patients should be instructed regarding after -care and provided with a [ADDRESS_802103] o f clinical care and should be documented on the Concurrent Medications eCRF. 
[IP_ADDRESS].[ADDRESS_802104]-TREATMENT PERIOD  
Special radiation isolation procedures for Treatment group  patients are not necessary following 
TheraSphere Treatment. The existence of a small amount of long -lived radioactive by[CONTACT_605648] a function of the production method13: The predomina nt by-products are Y -91, Y-88 and 
Cr-51 with respective half -lives of 59, 107 and 28 days. The 3 year accumulated dose to the patient’s liver 
is estimated to be 1/1000 of the planned treatment dose.  
Should a patient die or require surgery in the period immediately following -TheraSphere treatment the 
hospi[INVESTIGATOR_605617]. At 60 days after the T heraSphere calibration date, a 
surgeon explanting a treated liver in a procedure lasting one hour would be exposed to an estimated dose 
to the hands of <0.6  mrem. This is similar to estimated background doses from natural radiation sources 
which range from  0.5 to 0.8 mrem/day.  Institutional radiation safety guidelines for handling of the body 
and/or body tissues should be followed.    
[IP_ADDRESS]  SOC  SORAFENIB TREATMENT  
All patients will receive SOC treatment with sorafenib in accordance with the package insert.   Speci al 
attention should be paid to patients with hypertension or prolonged QT or at risk of developi[INVESTIGATOR_605618] (patients with a congenital long QT syndrome, patients treated with a high cumulative dose 
of anthracycline therapy, patients taking certain anti-arrhythmic medicines or other medicinal products 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 45 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, 
or hypomagnesemia). Blood pressure monitoring plus electrocardiogram with magnesium and calcium 
laboratory tests done at screening and first post -therapy visit then every 6 -8 weeks are recommended.  
Abnormal results or adverse events related to these conditions observed in study subjects should be 
recorded as adverse events. Therapi[INVESTIGATOR_605619] s uch adverse events should be recorded in the 
Concomitant Medication eCRF  
 Dosage adjustments and drug holidays will be determined to be in the patient’s best interest at the 
discretion of the physician.  Consider discontinuing sorafenib if QT/QTc increases over 500ms or increases 
to 60ms above the baseline reading.  All dosage adjustments must be logged on the Treatment Medication 
eCRF. 
Caution is recommended when considering concomitant administration of the following medications; 
please consult the sorafeni b summary of product characteristics /prescribing information  for details:  
 Warfarin, phemprocoumon or CYP2B6, CYP2C8 and CYP2C9 substrates (monitor regularly for 
changes in prothrombin time, INR or epi[INVESTIGATOR_605620])  
 Inducers of metabolic enzyme s such as rifampi[INVESTIGATOR_2513], St. John’s wort, phenytoin, carbamezepi[CONTACT_31806], 
phenobarbital, dexamethasone may increase  sorafenib metabolism and decrease sorafenib 
concentrations  
 UGT1A1 or UGT1A9 pathways metabolized compounds due to glucuronidation inhibition  
 
Contr ol group patients will start  SOC sorafenib therapy as soon as possible after randomization.  
Treatment group patients should initiate the SOC sorafenib regimen at least [ADDRESS_802105] progression 
with hepatic lesions amenable to further  TheraSphere treatment , sorafenib should be discontinued sev en 
(7) days prior to the administration of each subsequent TheraSphere treatment. If considered medically 
appropriate, SOC sorafenib therapy may be resumed after TheraSphere administration, but should only 
be resumed at least 2 weeks after TheraSphere has been administered .  
Sorafenib should be discontinued from seven (7) days prior through 48 hours after each angiographic 
procedure to reduce the risks of bleeding.  
9.2.16  EFFICACY IMAGING – CT/MRI  
Baseline efficacy imaging scans will be obtained during screening . Efficacy assessment scans will be taken 
in accordance with SOC clinical management guidelines every [ADDRESS_802106]  abdomen – must be performed with cuts of [ADDRESS_802107] criteria v1.1  (Appendix 3) .  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802108]  and pelvis  – mus t be performed with cuts of [ADDRESS_802109] criteria v 
1.1 (Appendix 3) . 
For Secondary Study Endpoints based on radiographic as sessment, the investigator will identify, read and 
measure hepatic lesions for size at Baseline using RECIST v 1.1 criteria .  At all subsequent follow -up visits, 
the images (using the same modality) will be read and measured and compared back to the Baseli ne 
images and then categorized as Complete Response, Partial Response, Stable, or Progressing at each time  
point using RECIST v 1.1 (Appendix 3) .   The se data will be captured on the eCRF and may be summarized 
showing tumor response over time.   
The tumor response , acco rding to the mRECIST criteria and based on a blinded centralized independent 
imaging assessment , will be recorded  as an exploratory endpoint . Investigators will not be required to 
perform mRECIST assessments.     
  
 
 
 
  
  
9.2.[ADDRESS_802110]  
The administration of treatment during the trial will be recorded throughout the trial  on the appropriate 
eCRF.  Start/stop dates, date s of change of dosage , and any drug holidays  will be recorded . 
9.2.[ADDRESS_802111]  
At every study visit new medications or changes in concurrent medications will be documented on the 
appropriate con current medication eCRF.  Documentation will include dosage, start/stop dates, date of 
change of dosage and any drug holidays . 
9.2.20   STUDY COMPLETION  
Patients complete the trial upon reaching the primary efficacy endpoint of death.  A patient may also 
decide he /she no longer wishes to participate in the trial. In accordance with the Declaration of Helsinki, 
and applicable state and federal regulations, a trial subject has the right to withdraw from the study at 
any time and for any reason. Every effort should be  made to have patients complete the study within the 
provisions of informed consent. However, the participation of the patient may be discontinued at any 
time during the study when, in the judgment of the investigator, sponsor or subject, it is appropriate .  
The reasons for study completion include : 
 Death of the patient  
 Patient’s desire for any reason to withdraw consent  
 Administrative reasons  
 It is considered necessary by [CONTACT_4687], for any reason  

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802112] to follow -up is not an adequate reas on for withdrawal. Patients should be encouraged to attend 
study visits until completion of the study or until a decision is taken to withdraw for one of the above -
noted reasons.  
If intolerance to the study treatment, the patient  should be under medical s upervision as long as deemed 
appropriate by [CONTACT_1963]. Similarly, if study treatment is discontinued due to an AE, the event 
will be followed until it resolves to the Investigator’s satisfaction or is considered stable. The details and 
reasons  for discontinuation must be carefully and completely documented. In either situation, the patient 
must be followed -up for survival until one of the reasons for study completion is met.    
10.0 STATISTICS  
10.1 SAMPLE SIZE ESTIMATE  
This study is a randomized open lab el multi -center Phase III adaptive trial using a group sequential design  
with  a primary endpoint of overall   survival (OS).  
The study is designed to detect a 3.5 month increase in median OS from 10.7 months in the control arm to 
14.2 months in the TheraSp here arm (i.e., hazard ratio  = 0.7 54), using a log rank test.  
A maximum of 417 deaths will yield 80% power to detect the target difference in median OS (ie, 
HR=0.7 54) with a two-sided alpha of 0.05 using a group sequential design with 2 interim analyses and 
stoppi[INVESTIGATOR_605621]=1 .5 (Jennison and Turnbull, 
2000)18.  It is estimated that a maximum of 520 patients will need to be recruited over 60 months, with an 
18 month additional follow -up period.  T his includes an adjustment to take account of an assumed 5% of 
patients who will be lost to follow -up and for whom a date of death is not recorded , and an assumed 
additional 5% of patients who will be  erroneously randomized because they did not meet the el igibility 
criteria at randomization . 
Sample size modification will be considered at the second interim analysis using  the approach described 
in Mehta and Pocock (2011)[ADDRESS_802113] statistic at the final analysis as 
recommended by [CONTACT_605649] (2006)17.  If the sample size is increased after the second interim 
analysis, the final analysis is planned when approximately, but no less than , [ADDRESS_802114] occurred , 
which will result in 80% power to detect an improvement in median OS from 10.7 to 1 3.7 months (ie, 
hazard ratio=0.7 81) using a log rank test with a final two-sided alpha of 0.0 363.  It is estimated that 
approximately  700 patients will need to be recruited over 66 months, with an 18 month additional follow -
up period , in o rder to observe 564 deaths .  This includes an adjustment to take account of an assumed 5% 
of patients who will be lost to follow -up and for whom a date of death is not recorded , and an assumed 
additional 5% of patients who will be  erroneously randomized be cause they did not meet the eligibility 
criteria at randomization . 
Sample size calculations were performed and verified with PROC SEQDESIGN, SAS 9.3.  
 
 
  

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 48 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  10.2 STATISTICAL ANALYSIS PLAN 
The statistical analysis plan will be written based on the final protocol and will be updated, as required, in 
association wit h any protocol amendments. The plan will include tables, listings and graphs and describe 
statistical programming considerations.  
10.2.1  POPULATIONS AND SUB-GROUP S 
 Modified Intent To Treat population ( mITT) 
A modified Intention To Treat (mITT) Population will be used to analyze all efficacy endpoints.  This 
population is defined as randomized patients who met the study eligibility criteria  at randomization . 
The analyses using this population  will be  performed  according to the  treatment group  to which  
patients were  randomiz ed. 
 Per Protocol Population (PP)  
The PP population comprises patients in the mITT Population without major protocol deviations 
which may affect the efficacy evaluation.  The analyses using this population  will be performed  
according to the treatme nt actually received.  
 Safety Analysis Population (SA)  
All randomized  patients who received study treatments at least once will be included in the safety 
analysis , and will be analyz ed according to the treatment actually received.  
  
 
 
 
 
10.2.[ADDRESS_802115] .    
10.2. 2.2 SECONDARY STUDY ENDPOINTS  
Time -to-progression  will be compared between the T reatment  and Control  groups from time of 
randomization to radiological progression (including new liver lesions and extra -hepatic lesions) according 
to RECIST v 1.1 criteria by [CONTACT_605650].   
Time -to-untreatable -progression  will be compared between  the T reatment  and Control  groups from 
randomization to radiological progression (including new liver lesions and extra -hepatic lesions)  accord ing 
to RECIST v 1.1 criteria by [CONTACT_605650] .  For patients randomized to the Treatment group, 
any liver lesion still amenable to TheraSphere treatment is not considered to be an untreatable 
progression. Untreatable progression will be define d as one of the following:  
o Intolerance to sorafenib  

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 49 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  o Occurrence of specific contraindications to sorafenib  
o Assessment of progression in the target lesions or occurrence of new lesions after  
treatment and, for patients randomized to the treatment group, a ma ximum of 2 re -
treatments with  TheraSphere   
o Occurrence of specific contraindications to TheraSphere  and or appearance of 
lung/intestinal shunts or anatomical constraints  not correctable by [CONTACT_605651] . 
o Confirmed extra -hepatic metastases  
o Deterioration of liver function (C hild Pugh score  >B7)  
o Clinical progression to ECOG performance status >1 . Such deterioration in PS should be 
observed at two subsequent evaluation s at 8 week intervals . 
 
Time to symptomatic progression (TT SP): from the time of randomization to ECOG performance status >[ADDRESS_802116] v 1.1 criteria  based on investigator assessment.  At Baseline, target 
tumors are identified, read and measured for size.  At all subsequent follow -up visits, the images (using 
the same modality) for the same target lesions will be read and measure d and compared back to the 
Baseline images and then  categorized according to the following table:  
 RECIST v 1.[ADDRESS_802117] RESPONSE  Change in the sum of diameter of target lesions  
CR Disappearance of all target lesions  
PR ≥30% decrease in the sum of diameters  of target lesions  
SD Neither CR nor PR nor PD  
PD ≥20% increase in the sum of the longest diameter of target lesions  from 
the smallest value on study.  
The sum of diameters must also demonstrate an absolute increase of at 
least 5mm e.g. Two lesions incre asing from 2mm to 3mm does not qualify.   
 
Quality of Life Assessments :  Functional Assessment  of Cancer Therapy – Hepatob iliary Questionnaire – 
FACT -Hep. Patients will be asked to complete the questionnaire at Baseline and each of the 8 week study 
visits . 
Safety  will be assessed at all visits for enrolled patients using v 4.0 of the National Cancer Institute’s 
Common Terminology for Adverse Events (NCI: CTAE). All adverse events, serious  adverse events , and 
unanticipated adverse device effects  as defined by [CONTACT_605652] .  These events will be documented and recorded on the Adverse Event eCRF using 
the NCI Common Toxicity Criteria for Adverse Events; CTCAE v.  4.0 standards , and will be coded using  the 
Medical Dictionary for Regulatory Activities (MedDRA) . 
    
    
   

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 50 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  o   
  
   
   
  
  
 
   
   
  
   
   
  
 
10.2.3  EFFICACY ANALYSIS  
The efficacy analyses will be performed on the mITT and PP populations.  
[IP_ADDRESS]  PRIMARY ENDPOINT STATISTICAL  ANALYSIS PLAN 
Overall survival (OS) time will be calculated as the interval between the randomiz ation date and the date 
of death for any cause, with censoring at the date of last contact [CONTACT_605653]. The Kaplan -Meier 
method will be used to estimate the OS curves in the two treatment group s; comparison between the 
curves will be performed using  the log-rank  test.  
Interim Analyses:  Two interim analyses of OS are planned to be performed by [CONTACT_115376] (IDMC)  based on group sequential stoppi[INVESTIGATOR_605622]=1.[ADDRESS_802118] interim analysis is planned at 
approximately, but no less than, 188 deaths, with a two-sided p -value ≤ 0.0151 allowing the study to be 
stopped early for efficacy.  A second interim analysis is planned at approximately, but no le ss than, 250 
deaths, with a two-sided p -value ≤ 0.0151 allowing the study to be stopped early for efficacy.   
A conditional power of less than  or equal to  15% at each of the interim analyses will result in the study 
stoppi[INVESTIGATOR_605609], using the me thod described in Proschan et al (2006)19. 
Sample size modification will be considered at the second interim analysis using the approach described 
in Mehta and Pocock (2011)16. 
Final Analysis:  The final analysis, without a sample size modification, is plan ned when approximately, but 
no less than, [ADDRESS_802119] occurred .  A two-sided p -value ≤ 0.[ADDRESS_802120] occurred , which will result in 80% power to detect an 
improvement in median OS from 10.[ADDRESS_802121] with a final two-sided alpha of 
0.0363. 

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 52 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019   Time to untreatable progression  (TTUP) will be calculated as the interval between the 
randomization date and the first occurrence of one of the events listed in Section  0. The Kaplan -
Meier method will be used to estimate the TTUP curves in the two treatment arms; comparison 
between the curves will be performed using  the log -rank test.   
 Time to symptomatic progression (TTSP)  will be calculated as the time from randomization to 
ECOG performance  status >1 with or without tumor progression (as defined in Section 0). The 
Kaplan -Meier me thod will be used to estimate the TTSP curves in the two treatment arms; 
comparison between the curves will be performed using the log -rank test . 
 Tumor response rate. The response probability will be estimated in each of the two treatment 
group s as proport ion of CR+PR (as de fined in S ection 0, tumor response  according to RECIST v 
1.1) over the total number of   mITT or PP patients  The disease control rate (ie, CR+PR+SD ) will 
also be compared between the tre atment arms.  Tumor response will be  compared using the 
continuity adjusted Newcombe -Wilson  test.  The corresponding 95% confidence limits will be 
calculated .  
 Quality of Life.  The total score of FACT -Hep will be calculated, the scores of each domain and 
each question at each time -point and their differences from baseline will be summarized for each 
treatment group . The two treatment group s will be compared applying a mixed model repeated 
measures analysis with the treatment , visit and the interaction betw een treatment  as factors, 
the baseline score as a covariate  and further adjusted for the interaction between baseline and 
visit. A deterio ration  in QOL  is defined as a [ADDRESS_802122].   The time to deterio ration in QoL (TTDQoL) will be calculated as the interval between 
the randomization date and deterioration in QoL.  The Kaplan -Meier meth od will be used to 
estimate the TTDQoL curves in the two treatment arms; comparison between the curves will be  
performe d using the log -rank test    
 
A detailed description of data censoring handling for patients will be defined in the Statistical Analysis 
Plan.  
 
10.2.4  SAFETY ANALYSE S 
The safety analyses will be performed on the SA population.  
All treatment emergent  adverse event s (TEAEs) , defined as events which were not present at baseline or 
worsened in severity following the start of treatment,  will be reported according to NCI Criteria.   The 
incidence of TEAEs will be summarized according to MedDRA coded primary system -organ class (SOC) and 
preferred term (PT).   The summaries will be presented overall (severity grades 1 -5) and for grade 3 
events and by [CONTACT_605654].  These summaries will present the number and percentage of 
patients reporting an adverse event for  each classification level as well as the number of events reported.  
 
Serious adverse events (SAE s) will be tabulated by [CONTACT_2948] .  
Laboratory values will be summarized by [CONTACT_605655].  
[IP_ADDRESS]  FEASIBILITY SAFETY ANALYSIS  
After th e first [ADDRESS_802123] 2 weeks of sorafenib therapy, a feasibility safety assessment will be 
conducted.  The IDMC  will review  the safety results of both the Control  and Treatment groups  in an 
unblinded fashion .  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802124] of disease progression in these patients may be understood by [CONTACT_605656]3 trial, as su mmarized in the SHARP trial publication and an EMEA14 overview 
of sorafenib including a safety review of the SHARP trial data.  
A consideration for stoppi[INVESTIGATOR_605623]  
 An unanticipated patient death definitely or pr obably  related to the sequential administration of 
TS followed by [CONTACT_44369], or  
 there is a pattern of serious toxicity clearly related to the sequential administration of TS 
followed by [CONTACT_605657] d isease of the enrolled population.  Such a 
toxicity pattern must be clearly different from, or more severe than, what might be expected from 
independent administration of the products. The potential adverse impact of any such pattern of toxicity 
on the surv ival or well being of the patient should be considered in the context of the safety and outcome 
expectations of patients with advanced HCC.  
10.2.[ADDRESS_802125] of these factors on OS.  Note: region and study site will not 
be included s imultaneously in the model due to collinearity.  
Should the impact of region, site or gender on OS be statistically and clinically relevant, the reasons for 
the observed differential treatment effect, such as patient demographic or clinical characteristics,  will be 
investigated and reported.  If the poolability of OS results are in direct question as a result of this 
sensitivity analysis, the primary endpoint (OS) will also be analyzed separately by [CONTACT_11338], site or gender.  
In addition, the primary endpoint (OS) will be analyzed separately by [CONTACT_415179] -US region. The specific 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802126].   
 
10.2.6  INDEPENDENT DATA  MONITORING COMMITTEE  
An Independent Data Monitoring Committee  (IDMC ) will be established to oversee the conduct of the 
study , will follow the FDA’s Guidance on IDMCs/ DSMBs  and comply with ISO [ADDRESS_802127] and review the feasibility safety analysis (per Section 10. 2.4.1) and will 
evaluate the data at interim analyses for consideration of stoppi[INVESTIGATOR_605624] -estimation at the second interim analysis .  The IDMC  will make formal 
recommendations to the study Sponsor at the time of the feasibility safety analysis , at the time of the 
interim analyses,  and during the conduct of the study  based on detailed decision rules specified in the 
IDMC charter . An IDMC  member or designate may act as the study independent medical monitor.  The 
IDMC  will evaluate the final study report . 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
11.0 DATA COLLEC TION AND MANAGEMENT  
11.1 ELECTRONIC DATA COLLECTION (EDC)  
Data from this trial will be captured on electronic case reporting forms (e CRFs), and will be entered into a 
validated clinical database.  An audit trail will be maintained to document all data changes i n the 
database.  Procedures will be followed to ensure the validity and accuracy of the clinical database.  

   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802128] s' eCRFs. 
Erro rs must be corrected in accordance with EDC data entry guidelines.  
12.0 ADVERSE EVENTS  
Adverse experience will be considered synonymous with the term adverse event and vice versa.  
12.1 ADVERSE EVENT DEFINITIONS  
Adverse experience will be considered synonymous with t he term adverse event and vice versa.   
12.1.1  DEFINITIONS OF AE/SAE  FOR DRUGS  
Adverse Event (AE)  
An AE is any untoward medical occurrence or undesirable event(s) experienced in a subject  or clinical 
investigation subject  that begins or worsens following administr ation of the study drug, whether or not 
considered related to the treatment by [CONTACT_093].  
An undesirable event(s) can be, but is not limited to, symptoms experienced by a subject  or objective 
findings, such as significant clinical laboratory abnorm alities.  
Serious Adverse Event (SAE)  
Any untoward medical occurrence that at any dose:  
 results in death;  
 is life -threatening (“life -threatening” refers to an event in which the subject  was at risk of death 
at the time of the event; it does not refer to an  event which hypothetically might have caused 
death if it were more severe);  
 requires inpatient hospi[INVESTIGATOR_1081];  
 results in a persistent or significant disability/incapacity; or  
 is a congenital anomaly/birth defe ct. 
 
Medical and scientific judgment should be exercised in deciding whether medical events that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_605625], should also be 
considered serious.  
 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 56 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  12.1.2  DEFINITIONS OF ADE/SADE/UADE  FOR DEVICES  
Adverse Device Effect (ADE)  
An adverse device effect is an adverse event (AE – previously defined) related to a medical device and 
includes any event resulting from insufficiencies or inadequacies in the instructions for use or the 
deployment, implantation, installation or malfunction of the device; any event that is the result of user 
error; or any potential adverse device effect whic h might have occurred is suitable action had not been 
taken or intervention had not been made or if circumstances had been less fortunate.  
Serious Adverse Device Effect (SADE)  
A Serious Adverse Device Effect is an adverse device effect that has resulted in  any of the consequences 
characteristic of a serious adverse event (SAE – previously defined) or might have led to any of these 
consequences if suitable action had not been taken; intervention had not been made or circumstances 
had been less fortunate.  
Unanticipated Adverse Device Event (UADE)  
An unanticipated adverse device effect is a ny serious adverse effect which by [CONTACT_5942], incidence, 
severity and outcome has not been identified in the risk assessment, the informed consent form as well as 
the protoc ol. 
12.[ADDRESS_802129] be recorded in the source 
document and on the appropriate case reports form(s) using medical terminology according to sponsor 
instructions.  
For each AE, the following info rmation will be recorded:  
 Adverse event  
 Serious/non -Serious  
 Severity  (Toxicity Grade)  
 Action taken  
 Relationship to study treatment  
 Expected/Unexpected  
 Date and time of onset  
 Date and time of resolution  
 
An expected adverse event is any AE, the nature or s everity of which is identified in the relevant Package 
Insert.  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802130] will be  followed until the AE has resolved to the investigator 's or 
physician sub -investigator's  satisfaction .  If a problem still exists, then the investigator or physician sub -
investigator  at his/her discretion will ask the subject  to come back to the clinic for further evaluation.  Any 
serious adverse events should be managed as discussed  in Section 12.3.  
Once the subject has been discharged from the study, the  investigator has no obligation to seek further 
follow -up with the subject  in order to identify new AEs. However, if the investigator becomes aware of an 
SAE that has occurred following the subject's discharge from the study and the investigator considers the 
SAE possibly, probably, or definitely related to a study drug or device, then the investigator should report 
the SAE as described in the protocol.  
12.2.1  CA[LOCATION_003]LITY (RELATIONSHIP TO MEDICAL  DEVICE ) ASSESSMENT  
The i nvestigator or physician sub -investigator must  indicate whether he/she  believe s the AE is not related, 
unlikely related, possibly related ( reasonable possibility that the medical device caused the AE), probably 
related, or definitely related to the medical device .  
The Investigator should pay careful attention to the attribution of relation for all adverse events.  Because 
there are many similar events between the TheraSphere and the  sorafenib safety profile, judgment of 
relation by [CONTACT_605658].  
An adverse event  becomes an adverse device effect when the adverse event  is considered associated with 
the use of the test device if the attribution is Possibly, Probably or Definitely Related .  Relation to 
TheraSphere (screenin g, procedure, embolization or radiation) is not appropriate for the Control  Group.  
Only those events with a possible, probable or definitely related attribution to TheraSphere will subject to 
expedited reporting. All other events documented in the trial w ill be addressed through periodic clinical 
trial reporting.  
 
12.3 SUBMITTING EXPEDITED SAFETY REPORTS  
Any SADE  or UADE (defined previously) must be reported by [CONTACT_605659] [ADDRESS_802131] the CRO using the coordinates specified in the study procedures.  
The SAE form provided by [CONTACT_605660]-investigator. The entire SAE form needs to be completed, if possible, to keep requests for additional 
information to a minimum. Patients experiencing SAE , SADE or UADE  should be followed clinically and 
with laboratory studies, if appropriate, until medical tr eatment and/or medical monitoring of the event 
is no longer required because the event resolves or stabilizes, returns to baseline if a baseline value is 
available, can be attributed to agents other than the study treatments or a referral for appropriate 
follow -up care has been made.  
The Investigator must promptly inform the IRB of all unexpected SAE or UADE. These events will be 
reported by [CONTACT_98304]’s designate as appropriate to the regulatory authorities according to 
relevant jurisdictional medic al device regulations. The Investigator will receive notification of these events 
across all study centers from the sponsor.  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802132] also be reported in the adverse event section of the eCRF. 
12.4 PERIODIC SAFETY REPORTING  
Adverse events will be recorded on the AE form and coded using NCI CTCAE v 4.0.  The investigator  or 
physician sub -investigator  will judge the severity of each  AE and  whether or not  it is treatment -related.   
All AEs that occur after randomization , including event s likely to be related to the underlying disease or 
likely to represent concurrent  illness, will be reported, including events present at Baseline which 
worsened during the trial.   
Periodic safety reports prepared by [CONTACT_605661]. The 
Investigator will be res ponsible for informing the IRB.  
12.5 EXPECTED ADVERSE EVENTS  
12.5.1  THERA SPHERE ADVERSE EVENT PROFILE  
TheraSphere has been approved for the treatment of HCC since 1999. Adverse events known to be 
related to the device o r the procedure listed in the current package insert (Appendix 1). Those adverse 
events identified in clinical trials investigating treatment with TheraSphere of liver lesions metastatic to 
non-HCC primary cancers are listed below in decreasing order of fr equency.  
Frequency  Description of Adverse Event (per NCI -CTCAE v 3.0)  
Common - >10%  Fatigue, pain, nausea, vomiting, anorexia and laboratory value abnormalities 
including increased alkaline phosphatase, AST, ALT, bilirubin and decrease albumin  
Infrequent  - <10%  Lymphopenia with no clinical sequelae; constipation, heartburn, weight loss, fever, 
ascites, muscle weakness, variations in hemoglobin, neutrophils and leukocytes, GI 
ulcer, dyspnea, arrhythmia, diarrhea, liver dysfunction, hypotension, insom nia, 
rigors/chills, sweating, distension, GI obstruction, hematoma, G I hemorrhage, 
pleural effusion  
Rare – < 1%  Alopecia, bruising, pruritis, rash, hot flashes, dehydration, taste alteration, 
hemorrhage, infection, dizziness, mood alteration, sensory neuropathy , somnolence, 
cough, urine color change, intraoperative injury, flu -like symptoms, tumor lysis 
syndrome, thrombosis, metabolic/laboratory abnormalities – creatinine, 
hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, lipase  
In addition, the foll owing events, which may or may not be related to the use of TheraSphere or the 
administration procedure, have been reported in clinical trials of treatment of primary or secondary liver 
cancer:  
Abdominal pain, dyspnoea, abdominal distention, anxiety, blurr ed vision, chills, hot flashes, bladder 
infection, lower extremity edema, gastrointestinal stoma complication including mild pain, hepatic 
encephalopathy, hepatorenal failure, edema, malaise, hepatic decompensation, hepatitis, duodenal ulcer, 
hypertension,  hypertension, aspi[INVESTIGATOR_59499], fall, gastrointestinal bleeding, elevated AFP, elevated 
LDH, elevated prothrombin time, elevated BUN, bacterial sepsis, hypoglycemia, abnormal platelets and 
electrolyte disturbances including hypercalcemia, hyperkalemia , hypomagnesemia, hyponatremia, low 
serum bicarbonate and low serum ch loride . 
12.5.2  SORAFENIB  ADVERSE EVENT PROFILE  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802133] an established IRB and clinical 
protocol review process in compliance with the appropriate regulations ( 21 CFR 56 or ISO [ZIP_CODE] )  so the 
clinical protocol can be adequately evaluated and approved at the institutional level.     
The institution m ust have appropriately qualified investigators, and clinical and administrative support 
staff in place to adequately conduct the trials according to GCP in general, and must have adequate 
expertise and staff in the treatment of p atients with hepatocellular  carcinoma  and the ability to 
adequately conduct clinical research under Good Clinical Practice Standards (GCP) consistent with the 
regulations of [ADDRESS_802134].  The required training will be specified by [CONTACT_456] .  Generally, 
an adequate level of experience consists of a minimum of five ( 5) TheraSphere administrations for sites 
without radioembolization experience and   at least three ( 3) administrations of TheraSphere  for sites 
experienced in radioembolization with d ifferent radioactive microsphere product . 
13.[ADDRESS_802135] (IRB) has reviewed and appro ved the protocol and the Informed Consent Form 
(ICF).  
The final IRB approved protocol, consent form, documentation of IRB approval of the consent and 
protocol, Study  Contract, Statement of Investigator, CVs of all investigators and study coordinators, 
records of protocol training, and all  other  study -related  required regulatory documentation  as described 
in the Sections below must also be maintained in the clinical study files for this trial . 
The Site  Principal Investigator [INVESTIGATOR_605626], that all study procedures are properly followed, and that all enrolled patients meet 
the eligibility criteria prior to enrollment  under this protocol.  
The Investigator is responsible for submiss ion of the protocol, informed consent form, any patient 
education materials, and any recruitment or advertising materials and the institution’s IRB.   
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 60 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019   Written approval of the protocol and Informed Consent Form must be obtained prior to 
recruitment of patien ts into the trial at each site and prior to administration of protocol 
treatment  to any randomized patient .   
 Written approval of the recruitment and advertising materials must have IRB approval before 
use.   
 The Investigator is responsible for obtaining a nd maintaining IRB approval at his facility and 
providing copi[INVESTIGATOR_605627].   
This protocol is a multi -center protocol and as such must remain consistent with all other sites.  
13.[ADDRESS_802136]  be obtained before study enrollment  can begin (with the exception of  
Final Report ). 
 Institutional Review Board Approval  
A copy of the protocol and any amendments, the proposed informed consent form (ICF), other written 
subject information  and any proposed advertising material must be submitted by [CONTACT_605662].  A copy of the written approval of the protocol and ICF must be received by [CONTACT_605663] s into the study and administration of protocol 
treatment . 
The investigator must submit and, where necessary, obtain approval from the IRB for all subsequent 
protocol amendments and changes to the ICF.  The investigator should notify the IRB of deviations from 
the protocol  and SAEs  as required by  [CONTACT_325514].  
The investigator will be responsible for updating the IRB about the status of the trial at least annually and 
obtaining any required approvals renewal throughout the duration of the study.  Copi[INVESTIGATOR_605628]. Copi[INVESTIGATOR_605629].  
 Institutional Review Board Membership Roster  
The inves tigator must submit a complete  and current roster of the IRB to the sponsor or designee .  Some 
institutions, on grounds of confidentiality, may  not release the IRB roster.  In such instances, the 
institution’s General Assurance Number, assigned by [CONTACT_605664], is an 
acceptable substitute.  
 Statement of Investigator  
The investigator will be required to sign and date a Statement of investigator form provided to them by 
[CONTACT_456] .  A copy of this form will be given to the inves tigator for their files.  The original form will be 
maintained by [CONTACT_456] . 
 Curriculum Vitae  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 61 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  The investigator will provide the sponsor  or designee  with his/her  up-to-date curriculum vitae (to within 
two years throughout the duration of the trial) and th ose of any sub-investigator s or staff personnel with 
significant trial responsibilities.  
 Laboratory Certification and Normal Values  
The Investigator will provide the sponsor  with the name [CONTACT_605670], copy of certification and a list of the normal range of 
values of all laboratory tests.  Any changes in laboratory, certification or normal ranges will be 
communicated promptly to the sponsor  or designee.  
 Financial Disclosure  
Financial disclosure statements will be completed for the investigator and all sub-investigator s to disclose 
potential conflicts of interest (per 21 CFR 54 and ISO [ZIP_CODE]) .  The investigator is responsible for ensuring 
completed and signed financial disclosure  forms, which are provided by [CONTACT_11153] .  A copy 
of the form(s) will be given to the investigator for their files.  The original form(s) will be maintained by 
[CONTACT_605665] e the start of the study 
and maintained for one year after study completion.  
 Final Report  
Upon completion of the clinical trial, a  final study report will be provided by [CONTACT_456]; The Investigator 
will prepare and submit to the IRB a final report, inclu ding final study report.   
13.4 SOURCE RECORDS AND STUDY DOCUMENTATION  
Investigators are required to p repare and maintain adequate source documentation.  Source 
documentation includes:  
 documents relative to the patient’s medical history that verify the eligibil ity criteria  
 records covering the pati ent’ participation in the study which  include but are not limited to basic 
identification information, results of physical examinations and diagnostic tests, therapy, device 
administration, con current  medication infor mation and visit/consult notes.  
The Investigator will initial and date all laboratory reports or initial and date statements at each study visit 
that all clinical laboratory data was reviewed.  
Federal regulations  concerning the period during which study re cords must be maintained by [CONTACT_605666]. Investigators are required to comply with their local regulatory 
authority for storage of study documentation.  For the purpose of this study the minimum retention for 
Study Document ation is a period of two (2) years after the later of the following:   (a) date on which the 
Study is terminated or completed; or (b) date records are no longer required to support a premarket 
approval application, notice of completion of a product developm ent protocol, or other application for 
research or marketing permit.   
 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802137]  completes the study.  The sponsor  or 
designee will provide the investigator with a copy of completed eCRFs for their files.  
In order to ensure the accuracy of data collected in the eCRFs, it is mandat ory that representatives of the 
sponsor , as well as representatives of a regulat ory agency ( eg, the Food and Drug Administration) or the 
institutional review board (IRB), have access to source documents ( ie, subject  records, subject  charts, and 
laboratory reports).  During the review of these documents, the anonymity of the subject  will be 
maintained with strict adherence to professional standards of confidentiality.  The sponsor  reserves the 
right to terminate the study for refusal of the investigator to supply source documentation of work 
performed in this clinical trial.  
13.[ADDRESS_802138] operating procedures of the sponsor or 
designee, which are designed to ensure adherence to good clinical practice (GCP) guidelines as required 
by [CONTACT_716]:  
1. World Medical Asso ciation (WMA), Declaration of Helsinki, Ethical Principles for Medical 
Research Involving Human Subjects, Adopted by [CONTACT_941] 18th WMA General Assembly, Helsinki, 
Finland, June 1964, and as amended at subsequent WMA General Assembly meetings.  
 
2. E6 Good Clinical Practice: Consolidated Guidance (International Conference on H armonization of 
Pharmaceuticals for Human Use [ICH], April 1996 governing drugs and ISO [ZIP_CODE] governing 
devices.  
 
3. Title 21 of the Code of Federal Regulations (21 CFR) Parts 50, 54, and 56. 
 
13.[ADDRESS_802139] OF RESEARCH  
The Sponsor will ensure that this trial is conducted in full conformity with the current revision of the 
‘Declaration of Helsinki’ , ISO [ZIP_CODE], the U.S. Code of Federal Regulations [ADDRESS_802140].  Investigator will maintain and release the records for review, provide access to the 
records and copi[INVESTIGATOR_242478], and will meet w ith the monitor as needed to discuss study progress and 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 63 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019  needs.  The Investigator should maintain the files suitable for inspection at any time by a trial monitor 
from the sponsor , or the appropriate regulatory authority , or designate representing these org anizations.  
13.7 INFORMED CONSENT  
An IRB approved  signed informed consent form (ICF) must be  obtained from a patient before that patient 
can enter the trial, and before any study related evaluations can be performed on that patient.  
The investigator is responsi ble for the creation of the ICF and must ensure that the informed consent 
adheres to the U.S Code of Federal Regulations, 21 CFR 50 , ISO [ZIP_CODE] or equivalent, as appropriate to 
his/her country .  The Investigator will ensure that the local IRB has approved th e protocol and the 
informed consent  prior to the initiation of the trial.  The signed informed consent from each patient must 
be kept in the patient ’s study file .   
The investigator or designee will review the treatment plan with the patient and the patien t will have an 
opportunity to ask questions regarding study procedures, the required visit schedule, risks/benefits of the 
use of the approved device (TheraSphere), and al ternative treatment options prior to signing the ICF.  The 
patient will receive a cop y of the signed informed consent to keep for their records.  Periodically during 
the study, revisions to the informed consent form may  be need ed.  Patients will be informed of such 
revisions and any revisions  must be signed and kept in the patient ’s study file.   
The acquisition of informed consent should be documented in the subject ’s medical record and the ICF 
should be signed and personally dated by [CONTACT_605667] (not necessarily by [CONTACT_3170] ).   
Patients for whom English is not their first language may need a written translation of the document 
and/or a patient advocate, according to the policies of the IRB.  The Investigator will provide the sponsor  a 
copy of the IRB approved translati on, if any.  
13.[ADDRESS_802141]/MRIs will be maintained or archived along with the medical chart for review for 
at least 2 years after premarket approval of the device.  
13.9 PATIENT PRIVACY AND CONFIDENTIALITY  
All collected patient data will be treated confidentially . Patients will be identified anonymously and in 
accordance with national laws and regulations.   Medical records relating to this trial, including those that 
are el ectronically maintained and those that may contain information that would identify an individual 
patient will remain confidential, but may be reviewed by, released, and/or transmitted to representatives 
of the hospi[INVESTIGATOR_307], the appropriate regulatory agency , the Sponsor or its agents, and the Independent Data 
Monitoring Committee  when reasonable and appropriate for the conduct of the trial.  
As part of the required content of the informed consent, the patient must be informed that his/her 
records will be reviewe d by [CONTACT_12408]/or a representative of the appropriate regulatory agency  and 
the Independent Data Monitoring Committee . The informed consent or related document will also state 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802142] 
(HIPAA) , [ADDRESS_802143] require a separate HIPAA waiver or authorization per institutional confidentially policies, it is the 
Inves tigator’s responsibility to obtain such permission from the patient in writing before the patient is 
entered into the trial.  
13.10  ADDITIONAL INVESTIGATOR RESPONSIBILITIES  
Additional Investigator responsibilities are noted in ISO 14155and in Section 11 of the US  21 CFR 812.100, 
812.110  and in country -specific guidelines and laws  and responsibilities for reporting of unanticipated 
adverse device events and deviations from the investigational plan per 812.150 as well as the following:  
 Ensure compliance with  institu tional and appropriate relevant jurisdictional  Radiation Safety 
policies and procedures  
 Assemble and coordinate a team that includes a designated co -investigator in all of the medical 
disciplines necessary for the efficient conduct of the protocol (oncolog y, interventional radiology, 
nuclear medicine, diagnostic radiology, etc).  
 Provide a trial coordinator who will be responsible for assisting the Investigator in meeting data 
collection and reporting requirement and for scheduling, management and follow -up of trial 
patients.  
 Provide adequate access to study materials for the sponsor  to monitor the trial at appropriate 
and convenient intervals and provide an adequate, secure area, within the study site facility for 
the sponsor  representative to conduct these monitoring activities.  
14.0 PROTOCOL DEVIATIONS  
It is vital to the success of the study that the investigator adheres to the details of the protocol . A protocol 
deviation is any change, divergence or departure from the  study protocol regardless  of the consequen ces 
to the patient or study outcomes.     
 
15.0 MAJOR AND MINOR PROTOCOL DEVIATIONS  
A major  protocol deviation  is defined as  a divergence from the protocol that materially (a) reduces the 
quality or completeness of the data, (b) makes the Informed Consent Form inaccurate, or (c) impacts a 
subject's safety, rights, or welfare , example :  
 
 Enrollment Violations   
 Eligibility criteria deviations  
 Inadequate informed consent Intentional repeated deviations from the protocol   
 TheraSphere Administration Violations: The raSphere treatment dose outside the range of  90- 
120 Gy ± 10%  
 Post -Treatment Violations: Administration of any liver -directed local regional therapy , except as 
specified by [CONTACT_760], following intra -hepatic progression .  
 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802144] research organization 
(CRO) contracted to provide such monitoring by [CONTACT_456] .  Data management and statistical analyses 
will be  the responsibility of the sponsor  who will contract with one or more organizations to manag e 
these functions.  
Before initiation of the trial, representatives from the sponsor will, together with the investigator, review 
the protocol and the facilities.  At trial initiation, the sponsor's representative will thoroughly review the 
protocol and go  over the eCRFs and electronic data entry procedures with the investigator(s) and other 
authorized staff.   
During the course of the trial, a study monitor or other authorized representatives of the sponsor will visit 
the investigator at suitable intervals .  The purpose of these visits will be to verify compliance with 
applicable government regulations and adherence to the protocol, ensure correct completion of the 
eCRFs. 
In order to perform his/her role effectively, the study monitor(s) must be given acces s to source 
documentation (eg, clinic charts, original laboratory records), which support data on the eCRF, and 
informed consent forms.  The monitor must be able to verify data appearing in the eCRFs against data in 
the subject's clinic chart (eg, chart no tes) or in printout forms (eg, laboratory results).  
17.[ADDRESS_802145] dose of sorafenib .   
 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} [ADDRESS_802146] Labeling  
a. US Package Insert  
b. CA Package Insert  
c. EU Instructions for Use  
 
2. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state -of-the-art 
brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and 
methodologic considerations. J Vasc Interv Radiol. 2006 Aug; 17(8):1251 -78. Review. Erratum in: J 
Vasc Interv Radiol. [ADDRESS_802147]; 17(10):1594.  
3. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, G wyther S, 
Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R,Lacombe D, Verweij J. New response evaluation 
criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):[ADDRESS_802148] the resulting Child Pugh Grade: A (well 
compensated disease) 5 -6 points; B (functional compromise, worsening disease)  7-9 points and C 
(decompensated disease) 10 -15 points.  
Parameter  1 point  2 points  3 points  
Bilirubin  <34 µmol/L  34–50 µmol/L  >50 µmol/L  
Albumin  >35 g/L  28-35 g/L  <28 g/L  
Prothrombin Time  <1.8 (INR) or <4 secs 
(Seconds over control)  1.8-2.2 (I NR) or 4 -6 
secs  >2.2 (INR) or >6 
secs  
Ascites  absent  Slight (medically 
controlled)  Moderate (poorly 
controlled)  
Encephalopathy*  None  Grade 1 -2 Grade 3 -4 
 
*Grades of Encephalopathy  
Grade 1 – Inverted sleep pattern; forgetfulness, agitation, irritability,  apraxia  
Grade 2 – Lethargy; Disorientation for time or place, Subtle personality change; 
Asterixis, ataxia  
Grade 3 – Somnolence but rousability; Disorientation as regards place; Asterixis, 
hyperactive reflexes, Babinski signs, muscle rigidity  
Grade 4 – Coma (unresponsive to verbal or noxious stimuli)  
 
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 67 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019   
REFERENCES  
                                                                 
1http://www.dep.iarc.fr/   accessed July , 2015   
 
2 http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm129234.htm , accessed June 22, 2010 at 09:[ADDRESS_802149] P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, 
Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris 
T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced 
hepatocellular carcinoma.  N Engl J Med. 2008 Jul 24;359(4):378 -90. PubMed PMID: 18650514.  
 
4 Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, 
Talwalkar J, Gores GJ; Panel of Experts in HCC -Design Clinical Trials. Design and endpoi nts of clinical trials 
in hepatocellular carcinoma. J Natl Cancer Inst. 2008 May 21;100(10):698 -711. Epub 2008 May 13. 
Review. PubMed PMID: 18477802.  
 
5 http://www.nccn. org/professionals/physician gls/PDF/hepatobiliary.pdf  accessed June 23 at 08:21 ET  
 
6http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=ab st detail view&confID=55&abstractID=
[ZIP_CODE]  accessed June 23, 2010 at 10:01 ET    M. Sherman, V. Mazzaferro, D. Amadori, J. Seitz, M. 
Moscovici, M. Shan, A. Nadel, D. Voliotis, J. M. Llovet, J. Bruix, on behalf of the SHARP investigators study 
group Efficac y and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular 
invasion or extrahepatic spread: A subanalysis from the SHARP trial. J Clin Oncol  26: 2008 (May [ADDRESS_802150]; 
abstr 4584)  
 
7 Salem R, Lewandowski RJ, Mulcahy MF, Riaz A,  Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, 
Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for 
hepatocellular carcinoma using Yttrium -90 microspheres: a comprehensive report of long -term out comes. 
Gastroenterology. 2010 Jan;138(1):52 -64. Epub 2009 Sep 18. PubMed PMID: 19766639.  
  
[ADDRESS_802151] P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, 
Gerken G, Antoch G. Radioembolization with yttrium -90 gla ss microspheres in hepatocellular carcinoma 
European experience on safety and long -term survival. Hepatology. 2010 Nov;52(5):[ADDRESS_802152] J, Al -Jiffry M, Hassanain M, Chaudhury P, Nudo C, Cabrera T, Valenti D, Metrakos P.  Combined 
Sorafenib and Yttri um-90 radio -embolization in the treatment of advanced HCC: preliminary survival data 
Poster Presentation (P -119) ILCA meeting, Montreal, Canada Sep 2010  
10http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpda
te2010.pdf  accessed November 15, 2010 at 12:20  
 
11  http://ecog .dfci.harvard.edu/general/perf stat.html accessed 3/24/2010  
 
12 Fischer L, et al.  The segments of the hepatic veins – is there a spatial correlation to the Couinaud liver 
segments?  Eur J Radiol 53(2):245 -255, 2005.  
 
13 Data on File, BTG  
   HCC Phase III Protocol  TS-103 
{STOP -HCC, Version 7.0 FINAL  Jul 22, 201 9} 68 
 
Biocompatibles [LOCATION_006] Ltd   CONFIDENTIAL 22JULY2019                                                                                                                                                                                                 
 
14Full Prescribing  information for Nexavar. Revised 11/2013. NDA [ZIP_CODE] Nexavar FDA Approved 22 Nov 
2013  
 
15http:// www.ema.europa.eu/docs/en GB/document library/EPAR -Scientific Discussion -
Variation/human/000690/WC500027710.pdf accessed November 12 , 2010 at 14:40  
 
16Mehta, C. R. and Pocock, S. J. (2011), Adaptive increase in sample size when interim results are 
promising: A practical guide with examples. Statist. Med., 30: 3267 –3284. doi: 10.1002/sim.4102  
 
17Burman and Sonesson (2006), Are flexible designs sound? Biometrics., 62: 664 -683 
 
18Jennison, C. and Turnbull, B. W. (2000), Group Sequential Methods with Appli cations to Clinical Trials, 
[LOCATION_001]: Chapman & Hall.  
 
19Proschan MA, Lan KKG, Wittes JT (2006), Statistical Monitoring of Clinical Trials: A Unified Approach. 1st 
edn. Springer: [LOCATION_003]  
 
20  Lencioni R, Llovet JM (2010), Modified RECIST (mRECIST) assessment f or hepatocellular carcinoma.  
Semin Liver Dis. 2010 Feb;30(1):[ADDRESS_802153] Tracking
Status: Original
             30-Jul-2019 | 10:53              Location: DocuSign
Signer Events Signature [CONTACT_605671]: 30-Jul-2019 | 11:09
Viewed: 30-Jul-2019 | 12:08 
Signed: 30-Jul-2019 | 12:[ADDRESS_802154] and Signature [CONTACT_59773]: 
      Not Offered via DocuSign
Sent: 30-Jul-2019 | 11:09
Viewed: 01-Aug-2019 | 18:00 
Signed: 01-Aug-2019 | 18:[ADDRESS_802155] and Signature [CONTACT_59773]: 
      Not Offered via DocuSign

Intermediary Delivery Events Status Timestamp
Certified Delivery Events Status Timestamp
Carbon Copy Events Status Timestamp
Sent: 01-Aug-2019 | 19:02
Viewed: 01-Aug-2019 | 19:[ADDRESS_802156] and Signature [CONTACT_59773]: 
      Not Offered via DocuSign
Witness Events Signature [CONTACT_108923]/Encrypted 01-Aug-2019 | 19:02
Certified Delivered Security Checked 01-Aug-2019 | 19:02
Signing Complete Security Checked 01-Aug-2019 | 19:02
Completed Security Checked 01-Aug-2019 | 19:[ADDRESS_802157] and Signature [CONTACT_81486]: 26-Jan-2018 | 11:38
Parties agreed to: 

By [CONTACT_605668], I agree that my electronic signature [CONTACT_605672]. Whenever I execute an electronic signature [CONTACT_605673], it has the same validity and meaning as my handwritten signature. I will not, at
any time repudiate the meaning of my electronic signature [CONTACT_605674].
Electronic Record and Signature [CONTACT_81486]: 15-Jan-2018 | 13:21
Parties agreed to: 
